Kevin R. Flaherty M.D. - medicine.umich.edu€¦ · Web viewKevin R. Flaherty, M.D., M.S....

Kevin R. Flaherty, M.D., M.S.Associate Professor of Internal Medicine

Division of Pulmonary & Critical Care MedicineUniversity of Michigan Health System

1500 E. Medical Center Drive, 3916 Taubman CenterAnn Arbor, MI 48109-0360

Phone: 734-936-5201; Fax: [email protected]

Title and Contents

Education and Training Page 2

Certification and Licensure Page 2

Academic, Administrative, and Clinical Appointments Page 2

Research Interests Page 3

Grants Page 3

Honors and Awards Page 7

Memberships in Professional Societies Page 7

Editorial Positions, Boards, and Peer-Review Service Page 8

Teaching Page 9

Committee, Organizational, and Volunteer Service Page 17

Visiting Professorships, Seminars, and Extramural Invited Presentations Page 17

Bibliography Page 20

Kevin R. Flaherty, M.D., M.S. 08/24/12 1

mailto:[email protected]

Education & Training

Education9/1985-4/1989 University of Dayton, Dayton, OH

B.S., Premedicine9/1989-5/1993 Indiana University School of Medicine, Indianapolis, IN

Doctor of Medicine10/1999-4/2001 University of Michigan, School of Public Health, Ann Arbor, MI

M.S., Biostatistics and Clinical Study DesignTraining6/1993-5/1994 Internship in Internal Medicine: Indiana University Medical Center6/1994-6/1996 Residency in Internal Medicine: Indiana University Medical Center7/1996-6/1997 Chief Medicine Resident: Indiana University Hospital7/1997-6/2000 Fellow in Pulmonary/Critical Care: University of Michigan Health

System, Ann Arbor, MI10/1999-4/2001 On the Job/On Campus Master’s in Public Health, Department of

Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI

Certification and Licensure

1994-1997 Medical Licensure, Indiana1996-2006 American Board of Internal Medicine, Internal Medicine 1696131997- Medical Licensure, Michigan Expires 1/31/20161997- Medical and Board of Pharmacy Licenses, Michigan Expires 1/31/20161997- Controlled Substance, DEA License Expires 1/31/20161999- ABIM Board Certified in Pulmonary Medicine 1696132001- ABIM Board Certified in Critical Care Medicine 169613

Academic, Administrative, and Clinical Appointments

7/2000-6/2001 Lecturer, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI

7/2001-8/2007 Assistant Professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI

7/2005- Associate Fellowship Director, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

9/2007- Associate Professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI

1/2011- Co-Director University of Michigan Interstitial Lung Disease Destination Clinic

7/2012- Vice-Chair, University of Michigan Institutional Review Board


Research Interests

1. Predicting outcome in idiopathic pulmonary fibrosis2. Diagnosis of diffuse parenchymal lung diseases3. Therapeutic trials in idiopathic pulmonary fibrosis4. Computer aided pattern recognition in high resolution computed tomography5. Chronic obstructive pulmonary disease

Grants

Present and ActiveNIH/NHLBIT32 HL00749Multidisciplinary Training Program in Lung DiseaseCo-Associate Director07/01/13-06/30/18 ($829,184 annual direct costs)

NIH/NHLBIK24 PA 10-061Forging a Road to Personalized Medicine in Interstitial Lung DiseasePI: K Flaherty (50% effort)06/18/12 – 01/30/17 ($175,969 annual direct effort)

NIH/NHLBIR01 HL091743Longitudinal, Computer, Assisted Analysis in IPFPI: K Flaherty (20% effort)08/01/08 – 07/31/13 ($296,309 annual direct costs)

NIH/NHLBI, 1 RC2 HL101740-01CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosisCo-PI’s: F Martinez, G Toews, K Flaherty (10% effort)09/30/2009 – 08/31/2012 ($3,008,100 annual direct costs)

Duke University (NIH prime)Anti-coagulant Effectiveness in Idiopathic Pulmonary Fibrosis, A Randomized, Double Blind, Placebo-controlled TrialPI: K Flaherty (5% effort)09/01/09 – 12/31/12 ($134, 836 annual direct costs)

Duke University (NIH prime)Prednisone, Azathioprine, N-acetylcysteine: A Trial that Evaluates Responses in IPF.PI: F Martinez, Co-I: K Flaherty (5% effort)10/01/09 – 09/30/12 ($80,816 annual direct costs)


NIH/NHLBI, P50 HL107177Prostanoids, Plasminogen Activation, and Personalized Therapeutics in IPFPI: M Peters-Golden, Co-I: K Flaherty (5% effort)05/01/11 – 04/30/13 ($284,955 annual direct costs)

NIH/NHLBI, HHSN26820118CLung Tissue Research ConsortiumP.I: F. Martinez, Co.I: K. Flaherty (5% effort)01/03/11 – 01/02/15 ($580,662 annual direct costs)

NIH/NHLBISubpopulations and Intermediate Outcome Measures in COPD Study SPIROMICS: Clinical CentersPI: F Martinez, Co-I: K Flaherty (8% effort)02/01/09 – 01/31/16 ($386,261 annual direct costs)

Brigham & Women’s Hospital (NIH prime)U01 HL105371Phase II Study of Inhaled Carbon Monoxide for the Treatment of IPFPI: F Martinez, Co-I: K Flaherty (10% effort)09/24/10 – 06/30/13 ($88,440 annual direct costs)

ImmuneWorksIW-001-01A Phase 1, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients with Idiopathic Pulmonary FibrosisPI: K Flaherty (3% effort)04/01/11 – 03/31/13 ($50,177 annual direct costs)

Intermune PharmaceuticalsPIPF-012 CapacityAn Open Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with IPF who complete the CAPACITY studiesPI: K Flaherty (3% effort)08/01/08 – 12/31/13 ($128,842 annual direct costs)

Centacor (Johnson & Johnson)CNTO888-PUL-2001A Phase 2, Mulitcenter, Mulitnational, Randomized, Double-blind, Placebo-controlled Parallel-group, Dose-ranging Study Evaluating the Efficacy & Safety of CNTO 888 Administered IntravenouslyPI: K Flaherty (2% effort)01/06/09 – 12/26/12 ($131,376 annual direct costs)


PendingNIH/NHLBI, RFA HL-13-003Defining Phenotypes of IPF Patients Responsive to Anti-IL13 TherapyCo-PI: K Flaherty$250,000 annual direct costs

Summary of Major Previous Grants

NIH/NHLBI, 1 U10 HL080371-01Novel Therapeutic Approaches in IPF (IPF Clinical Research Network)PI: F. Martinez; Co-I: K. Flaherty (25% effort)05/01/05 – 04/30/10 ($105,919 annual direct costs)

NIH/NHLBI U10 HL080371Clinical Skills Development CorePI: F. Martinez, PD: G Toews, Co-I: K. Flaherty (10% effort)05/01/05 – 04/30/10 ($ 89,109 annual direct costs)

NIH/NHLBI, R01 HL082480Innate and adaptive immunity in COPD exacerbationsPI: J. Curtis; Co-I: K. Flaherty (5% effort)09/30/05 – 09/29/10 (249,803 annual direct costs)

NIH/NHLBI, 01 HR-46162Lung Tissue Research ConsortiumPI: F. Martinez, Co-I: K. Flaherty (15% effort)12/01/06 – 01/30/09 ($299,656)

Cardiovascular Medical Research & Education Fund Lung Tissue Transplant & Processing CenterPI: D. Arenberg, Co-I: K. Flaherty (5% effort)07/01/06 – 06/30/11 ($125,000 annual direct costs)

Protocol GIPF-007InterMune PharmaceuticalsA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients with Idiopathic Pulmonary FibrosisPI: K. Flaherty (3% effort)05/05/04 – 12/31/07 ($56,227 annual direct costs)

Protocol C200-003CoTherix, Inc.A randomized, double-blind, placebo-controlled study to evaluate the safety and pilot efficacy of Iloprost inhalation solution in adults with abnormal pulmonary arterial pressure and exercise limitation associated with mild or moderate idiopathic pulmonary fibrosis


PI: K. Flaherty (3% effort)02/01/06 – 01/31/07 ($99,905)Protocol GC100800103Genzyme, Inc.A Phase I, Open-Label, Multi-Center, Single Dose, Dose-Escalating, Safety, Tolerability, and Pharmacokinetic Study of GC1008 in Patients with Idiopathic Pulmonary FibrosisPI: K. Flaherty (3% effort)10/20/05 – 08/31/07 ($49,996 annual direct costs)

NIH/NHLBI, R01 HL073728 IL-13 Fusion Cytotoxin as a Targeted Therapeutic for IIPPI: C Hogaboam; Co-I: K. Flaherty (5% effort)09/01/03-08/31/07 ($175,000 annual direct costs)

Clinical Trial AgreementUniversity of Pennsylvania/Eli LillyA Multicenter Prospective Cohort Study Examining the Role of Protein C (Activated) in Early ARDSPI: K. Flaherty (0% effort)06/17/04 – 12/31/05 (no direct dollars in 2004)

Protocol FGCL-MC3019-002Fibrogen Inc.A Phase I Study of the Safety Pharmacokinetics and Biologic Activity of Escalating Doses of FG-3019 in Subjects with Idiopathic Pulmonary FibrosisPI: K. Flaherty (2% effort)11/01/03 – 04/30/06 ($27,076 annual direct costs)

Protocol GC100800204 Genzyme, Inc.Protocol to Obtain Serum Samples from Patients with Idiopathic Pulmonary Fibrosis for Validation of Analytical Methods of Potential Biomarkers of Disease ActivityPI: K. Flaherty (2% effort)08/01/04 – 07/31/06 ($2,460 annual direct costs)

NIH/NHLBI, 1 K23 HL68713-01Prognostication in Idiopathic Interstitial PneumoniaPI: K. Flaherty (75% effort)12/01/01 - 11/30/06 ($124,000 annual direct costs)

NIH/NHLBI, 5 P50 HL56402-06SCOR in the Pathobiology of Fibrotic Lung DiseaseProject 1: Chemokine and Chemokine Receptors in IPFPD: G Toews; PI: C Hogaboam; Co-I: K Flaherty


(5% effort concurrent with K23)12/01/01 - 11/30/06 ($183,392 annual direct costs)

NIH/NHLBI, 5 P50 HL56402-06SCOR in the Pathobiology of Fibrotic Lung DiseaseProject 2: Eicosanoid Imbalance in Fibrotic Lung DiseasePD: G Toews; PI: M Peters-Golden; Co-I: K Flaherty (0% effort concurrent with K23)12/01/01 - 11/30/06 ($194,904 annual direct costs)

Honors and Awards

1985-1989 University of Dayton, Dayton, OH Magna Cum LaudeUniversity ScholarEverhard Scholarship for Preprofessional studentsUpperclassman Scholarship

1989-1993 Indiana University School of Medicine, Indianapolis, IN1989, 1990, 1992 Geneva Wise Endowed Scholarship1990 American Federation for Clinical Research Medical Student Award1991 AMA Medical Student scholarship1991 William and Fern Groves Hardiman Scholarship for Student Research1993 Alpha Omega Alpha1993 John B. Hickam Award for Internal Medicine

2010 American College of Chest Physicians – The Chest Foundation Robert McCaffree Humanitarian Award

2011 Marvin I. Schwarz Research Award for Pulmonary Fibrosis, Coalition for Pulmonary Fibrosis

2011 University of Michigan Medical School Award for Community Service

Memberships in Professional Societies

1985-1989 Alpha Epsilon Delta, President 1993American Medical Association

1993- American College of Physicians1997- American College of Chest Physicians1998- American Thoracic Society2003- Program Committee, Clinical Problems Assembly1999- European Respiratory Society2004- Michigan Thoracic Society2004-2006 Councilor-at-Large Officer, Michigan Thoracic Society, Executive Committee2006-2008 Treasurer, Michigan Thoracic Society2008-2010 President, Michigan Thoracic Society2010-2012 Past-President, Michigan Thoracic Society


Editorial Positions, Boards, and Peer-Review Service

Study Sections01/28/04 State of Pennsylvania Department of Health, Tobacco Settlement Grant Review09/07/05 Assign reviewers for interim review of State of Pennsylvania Department of

Health, Tobacco Settlement Grant2006-2008 National Institutes of Health, Protocol Review Committee for the Rare Diseases

Clinical Research Network05/20/06 National Institutes of Health, National Heart, Lung, and Blood Institute’s

Strategic Planning Process at the Division of Lung Diseases Level 1 Working Group on Theme #6: “New Investigator Workshop.”

07/28/09 Grand Opportunities" (RC2) (RFA-OD-09-004) - Molecular Profiling04/11/11 NHLBI Special Emphasis Panel/Scientific Review Group – Fibroproliferative

Lung Disease 2011/05 ZHL1 PPG-S (M1)11/27-28/12 NIH Idiopathic Pulmonary Fibrosis Strategic Planning Workshop02/01/13 NHLBI Study Section - Phase II Trials in Lung Disease

2013/05 ZHL1 CSR-F(M1)1

Reviewer2000- Chest2001- American Journal of Medicine2001- American Journal of Respiratory and Critical Care Medicine2001- Journal of the American Geriatrics Society (JAGS)2002- Respiratory Research2002- Journal of Critical Illness2004- European Respiratory Journal2006- Respiration2006- Arthritis Care & Research2008- Respiratory Research2008- Expert opinion on Medical Diagnostics2008- American Journal of Physiology

Editorial Boards2004- Section Editor, UpToDate in Pulmonary & Critical Care Medicine

Interstitial Lung Disease section2004-2008 American Journal of Respiratory and Critical Care Medicine2006-2010 Chest2009- Sarcoidosis Vasculitis and Diffuse Lung Diseases


Teaching Trainees2004-2006 Christopher Fraley, M.D., Pulmonary Fellow, (current position: private practice)2007 Charlene Fell, M.D. MSc FRCPC, Visiting Professor (current position: Clinical

Assistant Professor of Medicine, Division of Respiratory Medicine, University of Calgary, Alberta, Canada)

2008 Yoshio Ohtani, M.D., Visiting Professor (current position: Tokyo Medical and Dental University, Tokyo, Japan)

2008-2009 Anoop Nambiar, M.D., Pulmonary Fellow, University of Michigan2008-2009 Gregory Durm, Medical Student, University of Michigan2008-2009 Lora Reineck, M.D., House Officer, University of Michigan2008-2009 Thomas Scott-Craig, Medical Student, University of Michigan2008-2010 Melissa Miller, M.D., Pulmonary Fellow, University of Michigan2008-2011 Shelley Schmidt, M.D., Pulmonary Fellow, University of Michigan2011- Jamie Votava, M.D., House Officer, University of Michigan

University of Michigan1998- Clinical Skills Instructor, ‘Introduction to the Patient’ Medical School Course2000- Attending physician pulmonary consult service, pulmonary ward service2000- Attending physician critical care medicine unit2000- Attending physician medical procedures unit2000- Attending physician pulmonary function laboratory2001- Resident morning report2002- Intern morning report2004- Associate Director Pulmonary/Critical Care Fellowship Program2009- Resident Internal Medicine Board Review04/16/99 Pulmonary Research Conference, “Clinical progress with pulmonary fibrosis”12/16/99 Pulmonary Clinical Conference, “Mitochondrial myopathies at the University of

Michigan”01/18/00 Pulmonary Fellow’s Conference, “journal club”03/03/00 Pulmonary Research Conference, “IPF Clinical SCOR Update: Past, Present,

Future”08/02/00 Pulmonary Fellow’s Conference, “Exercise Testing”11/09/00 Pulmonary Clinical Conference, “Idiopathic pulmonary fibrosis: Clinical

progress”02/14/01 Pulmonary Fellow’s Conference, “Experimental design and biostatistics”08/07/01 Pulmonary Fellow’s Conference, “journal club”01/17/02 Pulmonary Clinical Conference, “The diagnosis and prognosis of idiopathic

interstitial pneumonia: The Michigan experience”09/20/02 Update in Pulmonary & Critical Care Medicine, “Non-specific interstitial

pneumonia (NSIP): myth or reality?”09/24/02 Pulmonary Fellow’s Conference, “Treatment trials in pulmonary fibrosis”01/17/02 Pulmonary Clinical Conference, “Idiopathic pulmonary fibrosis: SCOR update”08/05/03 Pulmonary Fellow’s Conference, “Interstitial Disease”


09/15/03 Update in Pulmonary & Critical Care Medicine, “UIP & NSIP: What we’ve learned from the University of Michigan SCOR”

01/21/04 Pulmonary Clinical Conference, “IPF SCOR Report: Approach to diagnosis & clinical trial update”

09/14/04 M2 Respiratory Sequence Lecture “Exercise Physiology & Cardiopulmonary Exercise Testing”

10/04/04 Update in Pulmonary & Critical Care Medicine, “Idiopathic pulmonary fibrosis: Recent developments in diagnosis and treatment”

10/21/04 Pulmonary Clinical Conference, “IPF SCOR Report: Approach to Diagnosis & Clinical Trial Update

03/22/05 Pulmonary Fellow’s Conference, “journal club”05/03/05 Pulmonary Fellow’s Conference, “journal club”09/20/05 Pulmonary Fellow’s Conference, “journal club”09/27/05 Pulmonary Fellow’s Conference, “Community acquired pneumonia”10/10/05 Update in Pulmonary & Critical Care Medicine, “Idiopathic pulmonary fibrosis:

Clinical trials update”11/10/05 Pulmonary Research Conference, “Idiopathic Pulmonary Fibrosis: New Insights

into the Diagnosis, Prognosis and Treatments”11/12/05 Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency

Update, “Current and Novel Therapies for COPD”02/07/06 Pulmonary Clinical Conference, “The Impact of Usual Care in Clinical Trials:

How to Select a Control Arm and Who Will Pay For It”09/25/06 M2 Respiratory Sequence Lecture “Exercise Physiology & Cardiopulmonary

Exercise Testing”09/25/06 Update in Pulmonary & Critical Care Medicine, “Diagnosis of Idiopathic

Interstitial Pneumonias”10/02/06 Attending Physician, Pulmonary Clinic at the Brighton Health Center09/04/07 M2 Respiratory Sequence Lecture “Exercise Physiology & Cardiopulmonary

Exercise Testing”09/24/07 Update in Pulmonary & Critical Care Medicine, Towsley Center, Ann Arbor, MI

“Update in Idiopathic Interstitial Pneumonia”10/04/07 Pulmonary Clinical Conference, “Clinical Trial Update: IPF and COPD”02/26/08 Allergy Clinical Conference, “Approach to the patient with suspected interstitial

lung disease”08/19/08 Patients and Populations course on Medical Decision-Making, Biostatistics and

Epidemiology, Diagnostic Reasoning, Small Group Leader to M1 Students09/02/08 Pulmonary Core Research Lecture Series, “Diffuse Parenchymal Lung Disease”10/03/08 Moderator, Update on Pulmonary and Critical Care Medicine, Towsley Center,

Ann Arbor, MI10/01/09 Update and Pulmonary and Critical Care Medicine, Towsley Center, Ann Arbor,

MI “Cryptogenic organizing pneumonia, Bronchiolitis obliterans organizing pneumonia”

09/30/10 Update and Pulmonary and Critical Care Medicine, Towsley Center, Ann Arbor, MI “Approach to treating the patient with IPF”

03/23/11 Resident Noon Conference, Ann Arbor, MI “Approach to the patient with suspected interstitial lung disease”


01/03/12 Pulmonary Clinical Conference, Ann Arbor, MI “Interstitial Lung Disease – Year in Review”

01/10/12 MICHR Post-doc Seminar, Ann Arbor, MI “Working with Industry”

InternationalNational05/19/03 Co-Chair, Master Clinicians - Pulmonary Fibrosis, American Thoracic Society

International Conference, Seattle, WA05/21/03 Facilitator, Poster Session – IPF: Clinical Challenges, American Thoracic Society

International Conference, Seattle, WA05/21/03 Invited Speaker, Symposium – Idiopathic Interstitial Pneumonias: An

international translational view, “Implications of Histologic variability on clinicopathological correlations in IIP,” American Thoracic Society International Conference, Seattle, WA

05/21/04 Invited Speaker, Postgraduate Course - Interstitial Lung Diseases: Current Concepts and Controversies, “Nonspecific Interstitial Pneumonia,” American Thoracic Society International Conference, Orlando, FL

05/22/04 Invited Speaker, Postgraduate Course - The Cutting Edge of Lung Fibrosis: How Our Current Understanding of Pathogenesis Is Leading To New Therapeutic Approaches, “The Rise and Fall of Steroids and Cytotoxic Therapy in IPF,” American Thoracic Society International Conference, Orlando, FL

05/25/04 Invited Speaker, Poster Session – Are Fibrotic NSIP and UIP really different diseases? , “Burning Controversies in the Diagnosis, pathogenesis and management of IPF,” American Thoracic Society International Conference, Orlando, FL

05/25/04 Co-Chair, Mini symposium – Idiopathic Interstitial Pneumonias: Hot topics in diagnosis and staging, American Thoracic Society International Conference, Orlando, FL

05/21/05 Invited Speaker, Postgraduate Course - Idiopathic Interstitial Pneumonias: From Functional Genomic Portraits to the Human Disease. Identifying Possible Molecular Targets for Intervention, “NSIP vs IPF, Are or Not the Same Diseases?” American Thoracic Society International Conference, San Diego, CA

05/20/06 Invited Speaker, Postgraduate Course – Diagnostic and Management dilemmas in Diffuse Interstitial Lung Disease. “Idiopathic Pulmonary Fibrosis (IPF) and Nonspecific Interstitial Pneumonia (NSIP): Key Issues of Diagnosis and Management” American Thoracic Society International Conference, San Diego, CA

05/21/06 Co-Chair, Symposium – IPF: Applying Data from Clinical Trials to Patient Care. “Exercise Testing in IPF: A Novel Therapeutic Endpoint” American Thoracic Society International Conference, San Diego, CA

05/21/06 Invited Speaker, Symposium – IPF: Applying Data from Clinical Trials to Patient Care. “Exercise Testing in IPF: A Novel Therapeutic Endpoint” American Thoracic Society International Conference, San Diego, CA

05/21/06 Co-Chair, Clinical Workshop – A Clinical-Radiographic-Pathologic Approach to the Patient with Suspected Idiopathic Interstitial Pneumonia. American Thoracic Society International Conference, San Diego, CA


10/21/06 Invited Speaker, Postgraduate Course - Current Concepts in the Diagnosis and Treatment of Interstitial Lung Disease. “The Role of Pulmonary Function Testing in the Diagnosis and Management of ILD,” CHEST 2006 Conference, Salt Lake City, UT

10/23/06 Invited Speaker, Satellite Symposium - Idiopathic Pulmonary Fibrosis: The Clinical Application of Emerging Insights. “Diagnosis of IPF: Emerging Insights and Clinical Implications” CHEST 2006 Conference, Salt Lake City, UT

10/24/06 Invited Speaker, Panel Discussion - Diagnosis and Management of Idiopathic Pulmonary Fibrosis in 2006. “Making an Accurate Diagnosis of IPF: What Are the Tools and How Do You Use Them?” CHEST 2006 Conference, Salt Lake City, UT

10/26/06 Invited Speaker, Interactive Session - Suspected Idiopathic Interstitial Pneumonia: A Clinical-Radiographic-Pathologic Approach. “Clinician” CHEST 2006 Conference, Salt Lake City, UT

05/20/07 Invited Speaker, Clinical Topics in Pulmonary Medicine – Controversies in IPF:PRO/CON Debate. “Distinguishing Fibrotic NSIP From IPF Is Important: Con”, American Thoracic Society International Conference, San Francisco, CA.

05/21/07 Facilitator, Thematic Poster Session – Connective Tissue Disease and the Lung, American Thoracic Society International Conference, San Francisco, CA.

05/21/07 Co-Chair, Invited Speaker, Clinical Workshop – Idiopathic Interstitial Pneumonia: A Multidisciplinary Approach to Diagnosis, American Thoracic Society International Conference, San Francisco, CA.

05/22/07 Co-Chair, Poster Discussion Session – IPF: Diagnosis and Prognosis, American Thoracic Society International Conference; San Francisco, CA.

05/22/07 Facilitator, Thematic Poster Session – Pulmonary Function Testing: Standards and Techniques, American Thoracic Society International Conference, San Francisco, CA.

05/23/07 Co-Chair, Clinical Topics in Pulmonary Medicine – IPF: Unraveling the Pathobiology, Formulating New Treatments, American Thoracic Society International Conference, San Francisco, CA.

05/18/08 Chairman, Poster Discussion Session, - Interstitial Lung Disease: Marker of Disease Activity, American Thoracic Society International Conference, Toronto, Ontario, Canada.

05/19/08 Chairman, Clinical Topics in Pulmonary Medicine – IPF Issues in Management from Diagnosis to Transplant, American Thoracic Society International Conference, Toronto, Ontario, Canada.

05/19/08 Invited Speaker, Division of Lung Disease/NHLB – IPF Network: New Insights IPF Pathogenesis and Therapy, “New Insights into Etiology and Implications for Evaluation”, American Thoracic Society International Conference, Toronto, Ontario, Canada.

05/20/08 Chairman, Invited Speaker, Clinical Workshop – The Multidisciplinary Diagnosis of Diffuse Lung Disease: Case Studies, “Introduction to a Multidisciplinary Approach”, American Thoracic Society International Conference, Toronto, Ontario, Canada.

05/20/08 Invited Speaker, Clinical Topics in Pulmonary Medicine – The Evolving Role of Anti-inflammatory Therapy in Lung Disease: A PRO/CON Debate Based on


Recent Therapeutic Trials, “CON: Anti-inflammatory Medications Should Be Used in IPF”, American Thoracic Society International Conference, Toronto, Ontario, Canada.

05/21/08 Author, Facilitator, Poster Session – Interstitial Lung Disease: Structure-Function Relationships, American Thoracic Society International Conference, Toronto, Ontario, Canada.

09/18/08 Invited Speaker, Austrian Society of Pneumnology, “Novel therapies in Idiopathic pulmonary fibrosis" Vienna, Austria.

09/18/08 Invited Speaker, Austrian Society of Pneumnology, "Current therapies in Lung and connective tissue disorders - Rheumatoid Arthritis and scleroderma" Vienna, Austria.

10/04/08 Invited Speaker, Oral Presentation, European Respiratory Society Annual Meeting, “New therapeutic strategies in idiopathic pulmonary fibrosis” Berlin, Germany.

10/05/08 Facilitator, Poster Session, European Respiratory Society Annual Meeting, “Computer assisted HRCT analysis in IPF patients detects change in ground glass opacity despite stable forced vital capacity”, Berlin, Germany.

10/26/08 Invited Speaker, American College of Chest Physicians Annual Meeting, “IPF/Usual Interstitial Pneumonia: A Biopsy is needed – Pro”, Philadelphia, PA.

10/26/08 Invited Speaker, American College of Chest Physicians Annual Meeting, “Focusing on Academic Goals during Junior Faculty Development”, Philadelphia, PA.

10/26/08 Invited Speaker, American College of Chest Physicians Annual Meeting, “Clinical Trials in Idiopathic Pulmonary Fibrosis”, Philadelphia, PA.

10/26/08 Invited Speaker, American College of Chest Physicians Annual Meeting, “Pulmonary Involvement with Rheumatoid Arthritis”, Philadelphia, PA.

11/06/08 Invited Speaker, 41st Congress of the Chilean Respiratory Society, “Idiopathic Pulmonary Fibrosis: Novel Therapy”, Chillán, Chile.

11/07/08 Invited Speaker, 41st Congress of the Chilean Respiratory Society, “Idiopathic Intersitial Pneumonia: IPF/UIP vs NSIP”, Chillán, Chile.

11/07/08 Invited Speaker, 41st Congress of the Chilean Respiratory Society, “Hypersensitivity Pneumonia”, Chillán, Chile.

11/08/08 Invited Speaker, 41st Congress of the Chilean Respiratory Society, “Pulmonary Manifestations of Collagen Vascular Disease”, Chillán, Chile.

03/20/09 Invited Speaker, 1st Annual Sakura Lung Conference, Tokyo Medical and Dental University, “Prognosis and Approach to Therapy in IPF”, Tokyo, Japan.

04/25/09 Invited Speaker, Internal Medicine 2009 Annual Meeting of the American college of Physicians, “Diffuse Parenchymal Lung Disease: An Update for the Internist (MTP 065)”, Philadelphia, PA.

05/17/09 Co-Chair, Clinical Year in Review – Interstitial Lung Disease, Pulmonary Vascular Disease, Pulmonary Infections, Cardiopulmonary Exercise Testing and Pulmonary Rehabilitation. American Thoracic Society International Conference, San Diego, CA

05/17/09 Author, Facilitator, Poster Discussion Session – Interstitial Lung Disease: Outcomes and Selected Clinical Issues. American Thoracic Society International Conference, San Diego, CA


05/18/09 Co-Chair, Clinical Year in Review – Sepsis, Mechanical Ventilation, Occupational/Environmental Lung Disease, Sleep. American Thoracic Society International Conference, San Diego, CA

05/19/09 Co-Chair, Clinical Year in Review – COPD, Treatment of Tobacco Dependence, Lung Cancer, Lung Transplantation. American Thoracic Society International Conference, San Diego, CA

05/20/09 Co-Chair, Clinical Year in Review – Pediatric Pulmonary and Critical Care, Cystic Fibrosis, Asthma, Pleural Disease. American Thoracic Society International Conference, San Diego, CA

05/20/09 Invited Speaker, Thematic Seminar Series: Interstitial Lung Disease, “Challenges in the treatment of IPF: Outcome Variables and Efficacy”, American Thoracic Society International Conference, San Diego, CA.

05/20/09 Invited Speaker, Idiopathic Pulmonary Fibrosis Network: New Insights into IPF pathogenesis and Therapy, “Ancillary Studies from the IPF Network”, American Thoracic Society International Conference, San Diego, CA.

10/27/09 Invited Speaker, American College of Rheumatology Annual International Meeting, “Development of Databases for the study of interstitial lung diseases”, Philadelphia, PA

10/29/09 Invited Speaker, Michigan State Medical Society Annual Meeting, “Approach to the patient with suspected interstitial lung disease” Troy, MI

02/27/10 Invited Speaker, American Thoracic Society State of the Art Course, “ILD – Managing Patients without a Tissue Diagnosis”, Miami, FL

04/25/10 Invited Speaker, 50th Annual Japanese Respiratory Society Meeting, New Strategy Against IPF, “Fibrotic interstitial pneumonia such as IPF and NSIP: current topics on their clinical courses and the surrogate markers of the prognosis or the therapeutic effectiveness”, Kyoto, Japan

05/14/10 Invited Speaker, American Thoracic Society Post Graduate Course, Practical Issues in the Management of ILD, “When not to biopsy interstitial lung disease” American Thoracic Society International Conference, New Orleans, LA

05/16/10 Co-Chair, Clinical Year in Review – Interstitial Lung Disease, Pulmonary Vascular Disease and Venous Thromboembolism, Diagnostic Imaging, Lung Cancer. American Thoracic Society International Conference, New Orleans, LA

05/16/10 Invited Speaker, Clinical Year in Review Session, “Interstitial Lung Disease.” American Thoracic Society International Conference, New Orleans, LA

05/17/10 Co-Chair, Clinical Year in Review – Bronchiectasis, Mycobacterial Infections of the Lung, Sleep Disordered Breathing, Lung Transplantation. American Thoracic Society International Conference, New Orleans, LA

05/17/10 Invited Speaker, “IPF Disease Progression, Staging, Monoitoring and Prognostic Factors: What to Look for and what to Follow.” American Thoracic Society International Conference, New Orleans, LA

05/18/10 Co-Chair, Clinical Year in Review – Pulmonary Rehabilitation, Respiratory Health Effects of Smoking, Genetics of Lung Disease, COPD. American Thoracic Society International Conference, New Orleans, LA

05/18/10 Co-Chair, Clinical Trials in IPF: Past, Present, Future. American Thoracic Society International Conference, American Thoracic Society International Conference, New Orleans, LA


05/19/10 Co-Chair, Clinical Year in Review – Advances in Critical Care Medicine, End of Life Care in the Crtically Ill Patient, Asthma, Mechanical Ventilation. American Thoracic Society International Conference, New Orleans, LA

05/19/10 Invited Speaker, “Clinical, Radiographical, and Pathological predictors of Disease Progression.” American Thoracic Society International Conference, New Orleans, LA

10/30/10 Invited Speaker, Post-Graduate Course – An Integrated and Comprehensive Approach to the Management of Advanced Lung Diseases, “Advanced Interstitial Lung Diseases, What are the Treatment Options.” American College of Chest Physicians Annual Meeting, Vancouver, BC, Canada

10/31/10 Invited Speaker, “Rheumatoid Arthritis in the Lung.” American College of Chest Physicians Annual Meeting, Vancouver, BC, Canada

10/31/10 Chair, Connective Tissue Disease and the Lung. American College of Chest Physicians Annual Meeting, Vancouver, BC, Canada

11/01/10 Invited Speaker, “Investigational Agents for the Treatment of IPF: An Updte for 2010” American College of Chest Physicians Annual Meeting, Vancouver, BC, Canada

03/03/11 Invited Speaker, American Thoracic Society State of the Art Course, “ILD – Managing Patients without a Tissue Diagnosis”, San Diego, CA

05/15/11 Co-Chair, Clinical Year in Review 1 – Interstitial Lung Disease, Occupational Lung Disease, Education of Residents and Fellows, Pediatrics. American Thoracic Society International Conference, Denver CO

05/16/11 Co-Chair, Clinical Year in Review 2 – Lung Cancer, Sleep Apnea, Interventional Pulmonary/Pleural Disease, Cystic Fibrosis. American Thoracic Society International Conference, Denver CO

05/17/11 Co-Chair, Clinical Year in Review 3 – Mechanical Ventilation, ARDS, Non-Pulmonary ICU, Quality performance assessment metrics in your practice. American Thoracic Society International Conference, Denver CO

05/18/11 Co-Chair, Clinical Year in Review 4 – Asthma, COPD, Host-microbe interactions in airway disease, pulmonary vascular. American Thoracic Society International Conference, Denver CO

07/12/11 Invited Speaker, Pulmonary Fibrosis Foundation FDA Leadership Summit, “Progression of Disease, physiologic, radiologic, acute exacerbation” . Bethesda, MD

09/26/11 Invited Speaker, “The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis” European Respiratory Society International Meeting, Amsterdam, Netherlands

09/27/11 Invited Speaker, “Advances in Interstitial Lung Diseases” European Respiratory Society International Meeting, Amsterdam, Netherlands

10/24/11 Invited Speaker, “Literature Review, Interstitial Lung Diseases” American College of Chest Physicians International Meeting, Honolulu, HI.

10/25/11 Invited Speaker, “What does NSIP look like? Making the Clinical/Radiologic/Pathologic Diagnosis” American College of Chest Physicians International Meeting, Honolulu, HI

12/03/11 Invited Speaker, “Idiopathic Pulmonary Fibrosis, Establishing a Confident Diagnosis”, IPF Summit 2011, Chicago, IL


02/18/12 Invited Speaker, “Approach to the patients with suspected interstitial lung disease”, Oregon Thoracic Society, Bend, OR

02/18/12 Invited Speaker, “Treatment of Idiopathic Pulmonary Fibrosis, Where are we now?”, Oregon Thoracic Society, Bend, OR

05/19/12 Invited Speaker, “To biopsy or not to biopsy”, Post Graduate Course: Evaluation of interstitial lung disease more bang for your buck. American Thoracic Society International Conference, San Francisco, CA

05/20/12 Invited Speaker, “Monitoring and Predicting Prognosis in IPF”, American Thoracic Society International Conference, San Francisco, CA

05/22/12 Invited Speaker, “Idiopathic NSIP”, American Thoracic Society International Conference, San Francisco, CA

05/22/12 Co-Chair Poster Discussion, “Pathogenesis, biomarkers, and risk factors for interstitial lung disease: from bench to bedside” , American Thoracic Society International Conference, San Francisco, CA

05/23/12 Co-Chair Mini-symposium, “Hypersensitivity pneumonitis: recent advances, future directions” , American Thoracic Society International Conference, San Francisco, CA

05/23/12 Invited Speaker, “Computer aided CT analysis in the IPFnet PANTHER study”, American Thoracic Society International Conference, San Francisco, CA

10/20/12 Invited Speaker, “Interstitial Lung Disease: Update on Diagnosis and Management of Idiopathic Interstitial Pneumonias”, American College of Chest Physicians International Conference, Atlanta, GA

10/22/12 Invited Speaker, “Pathophysiology of IPF”, American College of Chest Physicians International Conference, Atlanta, GA

10/22/12 Invited Speaker, “Selecting treatment for NSIP based on current evidence”, American College of Chest Physicians International Conference, Atlanta, GA

02/20/13 Invited Speaker – Pulmonary Grand Rounds, “Idiopathic Pulmonary Fibrosis 2013 – Diagnosis and Treatment” Thomas Jefferson University Hospital, Philadelphia, PA

03/22/13 Invited Speaker – Pulmonary Grand Rounds, “Idiopathic Pulmonary Fibrosis 2013 – Diagnosis and Treatment” North Shore Hospital, New York, NY


Committee, Organizational, and Volunteer Service

Local2007- Volunteer Physician, Faith Medical Clinic, Pinckney, MI2008- St. Mary High School Youth Group Leader, Pinckney, MI

Institutional2002-2006 GCRC Advisor Committee, University of Michigan General Clinical Research

Center2003- Medical School Institutional Review Board (IRBMED) for investigations

involving human subject2005-2006 Taubman Clinic Satisfaction Committee, University of Michigan Department of

Internal Medicine2006-2007 GCRC Advisory Committee Interim Chair, University of Michigan General

Clinical Research Center2007-2008 GCRC Advisory Committee Chair, University of Michigan General Clinical

Research Center2007- Fellowship Education Committee, University of Michigan2007- Shape of the Fellowship Program Committee, University of Michigan2007- Core Research Conference Committee, University of Michigan2007- Core Pulmonary Conference Committee, University of Michigan2011- Medical Student Run Free Clinic Advisory Board, University of Michigan

National2007- Clinical Problems Program Committee, American Thoracic Society2007-2008 Chair Nominating Committee, Clinical Problems, American Thoracic Society2008-2010 Co-Chair Year in Review Committee, American Thoracic Society2009-2010 Chair elect Clinical Problems Program Committee, American Thoracic Society2009- American College of Chest Physicians, Interstitial and Diffuse Lung Disease

NetWork Committee Member2010-2011 Chair Clinical Problems Program Committee, American Thoracic Society2011- American College of Chest Physicians, Interstitial and Diffuse Lung Disease

NetWork Steering Committee member

Visiting Professorships, Seminars, and Extramural Invited Presentations

Extramural Invited Presentations1991 Invited Speaker, 32nd Annual National Student Research Forum, Galveston, Texas1997 Invited Speaker, Tri-State Thoracic Conference, Lake Geneva, Wisconsin,

‘Diagnosis of Pulmonary Embolism.’1998 Invited Speaker, Tri-State Thoracic Conference, Lake Geneva, Wisconsin,

‘Unexplained Dyspnea.’ and ‘Pulmonary Manifestations of Lupus.’06/07/00 Invited Speaker, Great Lakes Chapter of the International Transplant Nurses

Society, 'Lung transplant vs. lung volume reduction surgery for severe emphysema'


09/08/01 Invited Speaker, Tri-State Thoracic Conference, Egg Harbor, Wisconsin, "Interstitial lung disease"

09/28/01 Invited Speaker, Pulmonary Medicine: An Update for Primary Care Physicians, East Lansing, Michigan, “Approach to patients with interstitial lung disease"

11/16/01 Invited Speaker, Ingham Medical Center, "Community Acquired Pneumonia: The ATS perspective"

04/20/02 Invited Speaker, 7th Annual Symposium on Allergy, Asthma and Immunology, Fort Wayne Medical Institute, Fort Wayne, IN, "COPD and Chronic Bronchitis,

05/21/02 Invited Speaker, American Thoracic Society Annual Meeting, Sunrise Seminar, Atlanta, GA, "Prognostication in pulmonary fibrosis: How and why?"

09/09/02 Invited Speaker, Flower Hospital, General Medical Staff Meeting, Sylvania, OH, "Community acquired pneumonia"

09/29/02 Invited Speaker, Ozark Chest Conference XXII, Missouri Thoracic Society, Lake of the Ozarks, MO, "Cardiopulmonary exercise testing/Exercise physiology"

09/30/02 Invited Speaker, 15th Annual Update on Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, "Non-specific interstitial pneumonia: Myth or reality?"

11/01/02 Invited Speaker, Pulmonary, Critical Care, and Sleep Disorder Symposium, St. Charles Mercy Hospital, Oregon, OH, “COPD: Management of patients with recurrent exacerbation and hospitalization”

11/14/02 Invited Speaker, Indiana Thoracic Society, “Recent advances in the diagnosis and determining prognosis in patients with idiopathic pulmonary fibrosis”

02/12/03 Invited Speaker, Update in Pulmonary Medicine, Genesys Regional Medical Center, Grand Blanc, MI, “Management of COPD”

02/26/03 Invited Speaker, 11th Annual Pulmonary Symposium, St. John Northeast Community Hospital, Detroit, MI, “Collagen vascular associated interstitial lung disease”

05/01/03 Invited Speaker, Resident’s Conference, St. Vincent’s Medical Center, Toledo, OH, “Approach to the patient with suspected interstitial lung disease”

03/12/04 Invited Speaker, Annual Pulmonary and Lung Cancer Conference, Ingham Regional Medical Center, E. Lansing, MI, “Treatment options for the patient with advanced emphysema: What can we do when medications are not enough?”

04/13/04 Invited Speaker, Michigan Society for Respiratory Care 46th Annual Spring Seminar, Lansing, MI, “Prevention and treatment of COPD exacerbations”

04/13/04 Invited Speaker, Michigan Society for Respiratory Care 46th Annual Spring Seminar, Lansing, MI, “Surgical Therapy for COPD: Transplant and lung volume reduction surgery”

09/15/04 Invited Speaker, 7th Annual Clinical Chest Conference, William Beaumont Hospital, Royal Oak, MI “Pulmonary Fibrosis—I Will Not be Ignored”

10/11/04 Invited Speaker, Michigan Society of Respiratory Care, Bavarian Inn Lodge of Frankenmuth, Frankenmuth, MI “IPF & Pulmonary Rehabilitation”

11/16/04 Invited Speaker, Flower Hospital, Sylvania, OH, General Medical Staff Meeting, “Update on Acute Exacerbation of Chronic Bronchitis"

11/18/04 Invited Speaker, Kalamazoo Center for Medical Studies, Grand Rounds, Kalamazoo, MI, “COPD”


11/19/04 Invited Speaker, Ingham Regional Medical Center, 18th Annual Infectious Disease Update, East Lansing, MI, “Approach to the patient with Acute Bronchitis”

12/10/04 Invited Speaker, Hurley Medical Auditorium, Grand Rounds, Flint, MI, “Obstructive Lung Disease: Why the etiology matters”

01/07/05 Invited Speaker, St. Mary Mercy Hospital CME Conference, Livonia, MI, “Interesting Case Review COPD/ Emphysema/ Bronchitis/Asthma”

03/02/05 Invited Speaker, Garden City Hospital Grand Rounds, Garden City, MI, “Community Acquired Pneumonia”

04/04/05 Invited Speaker, North Oakland Medical Center Visiting Professor Rounds, Pontiac, MI, “Update on Treatment of Pneumonia”

02/07/06 Invited Speaker, Colorado Academy of Physician Assistants, Englewood, CO, “Acute Exacerbations of Chronic Bronchitis”

03/02/06 Invited Speaker, St. Joseph Mercy Oakland, Internal Medicine Noon Conference, “Interstitial Pulmonary Fibrosis”

03/08/06 Invited Speaker, SouthEast Michigan Pharmacy Association, Southfield, MI, “Asthma Update”

03/17/06 Invited Speaker, Ingham Regional Medical Center, Department of Internal Medicine Residents and Staff, “Updates in the Management of COPD”

03/17/06 Invited Speaker, Oakwood Hospital & Medical Center, Department of Internal Medicine Grand Rounds, Dearborn, MI, “Interstitial Lung Disease”

03/20/06 Invited Speaker, Saginaw Family Physicians Association, Saginaw, MI, “Pulmonologist Perspective on COPD”

11/17/06 Invited Speaker, Crittenton Hospital, Pneumonia Grand Rounds, Rochester Hills, MI “Community Acquired Pneumonia”

02/02/07 Invited Speaker, New York State Thoracic Society, West Point, NY “Multidisciplinary Approach to Diagnosis & Treatment of Interstitial Lung Diseases”

03/02/07 Invited Speaker, New Jersey Thoracic Society, Iselin, NJ “Idiopathic Pulmonary Fibrosis is a Treatable Disease: Con” Pro-Con Debate

03/22/07 Invited Speaker, St. Mary’s Regional Medical Center, Internal Medicine Resident Conference, Saginaw Mi, “Approach to Treating the Patient with COPD”

09/23/07 Invited Speaker, Coalition for Pulmonary Fibrosis, Washington, D.C. “Living with Idiopathic Pulmonary Fibrosis”

10/01/07 Invited Speaker, St Mary’s School Assembly, Pinckney, MI “Keeping Fit and Having Fun, Be a Fit Kid”

07/18/08 Invited Speaker, Medical Staff Grand Rounds, University of Tennessee Health Science Center at Memphis, Memphis TN “Multidisciplinary Approach to Diagnostic and Treatment of ILD”

09/16/08 Medical Staff Grand Rounds, St. John’s Hospital, Detroit, MI “Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment”

01/20/09 Invited Speaker, Medical Staff Grand Rounds, Wayne State Medical School, Detroit, MI “Idiopathic Pulmonary Fibrosis: Approach to Diagnosis and Treatment”

03/07/09 Invited Speaker, Mid-Michigan Medical Center, Primary Care Symposium, Midland, MI “Chronic Obstructive Pulmonary Disease”


03/11/09 Visiting Professor, Internal Medicine Grand Rounds, University of Cincinnati, Cincinnati, OH “Approach to the Patient with Suspected Interstitial Lung Disease”

03/12/09 Visiting Professor, Pulmonary Grand Rounds, University of Cincinnati, Cincinnati, OH “Approach to Treatment of Idiopathic Pulmonary Fibrosis”

08/28/09 Invited Speaker, Association of Specialty Professors. Workshop on Idiopathic Pulmonary Fibrosis in Older Adults Washington, DC “Environmental factors: Cigarette smoking as a risk factor and others (i.e. pollution, particulate matters, metal exposure)”

11/17/11 Visiting Professor/Invited Speaker, “Diagnostic Approach to Patients with Suspected Interstitial Lung Disease”, MetroHealth Medical Center, Cleveland, OH

11/18/11 Visiting Professor/Invited Speaker, “Approach to treating patients with idiopathic pulmonary fibrosis”, MetroHealth Medical Center, Cleveland, OH

03/22/12 Visiting Professor/Invited Speaker, “Diagnosis and Treatment of Interstitial Lung Disease” University of Arizona Medical Center, Tucson, AZ

04/06/12 Visiting Professor/Invited Sparer, “Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis in 2012” Medical College of Wisconsin, Milwaukee, WI

08/16/12 Invited Speaker, “Emerging Treatments: New Hope for IPF Patients”, VA Grand Rounds, Coatsville, PA.

09/22/12 Invited Speaker, “Idiopathic Pulmonary Fibrosis: Where are we now?”, Emerging Challenges in Primary Care 2012, Ft. Lauderdale, FL.

02/20/13 Invited Speaker – Pulmonary Grand Rounds, “Idiopathic Pulmonary Fibrosis 2013 – Diagnosis and Treatment” Thomas Jefferson University Hospital, Philadelphia, PA

03/22/13 Invited Speaker – Pulmonary Grand Rounds, “Idiopathic Pulmonary Fibrosis 2013 – Diagnosis and Treatment” North Shore Hospital, New York, NY

Bibliography

Peer-Reviewed Journals and Publications

1. Flaherty KR, Bates JR. Mitral regurgitation caused by chronic ergotamine use. Am Heart J. 1996;131(3):603-6.

2. Martinez FJ, Strawderman RL, Flaherty KR, Cowan M, Orens JB, Wald J. Respiratory response during arm elevation in isolated diaphragm weakness. Am J Respir Crit Care Med. 1999;160(2):480-6.

3. Flaherty KR, Kazerooni EA, Martinez FJ. Differential diagnosis of chronic airflow obstruction. J Asthma. 2000;37(3):201-23.

4. Martinez FJ, Brennan-Martinez C, Flaherty KR. Bronchitis in the elderly: when and in whom to use antibiotics. Clin Geriatr. 2000;8:61-82.


5. Flaherty KR, Kazerooni EA, Curtis JL, Iannettoni M, Lange L, Schork MA, Martinez FJ. Short-term and long-term outcomes after bilateral lung volume reduction surgery : prediction by quantitative CT. Chest. 2001;119(5):1337-46.

6. Flaherty KR, Martinez FJ. Diagnosing interstitial lung disease: a practical approach to a difficult problem. Cleve Clin J Med. 2001;68(1):33-4, 7-8, 40-1, 5-9.

7. Flaherty KR, Martinez FJ, Travis W, Lynch JP, 3rd. Nonspecific interstitial pneumonia (NSIP). Semin Respir Crit Care Med. 2001;22(4):423-34.

8. Flaherty KR, Saint S, Fendrick AM, Martinez FJ. The spectrum of acute bronchitis. Using baseline factors to guide empirical therapy. Postgrad Med. 2001;109(2):39-47.

9. Flaherty KR, Toews GB, Lynch JP, 3rd, Kazerooni EA, Gross BH, Strawderman RL, Hariharan K, Flint A, Martinez FJ. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med. 2001;110(4):278-82.

10. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, Martinez FJ. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001;164(9):1722-7.

11. Flaherty KR, Wald J, Weisman IM, Zeballos RJ, Schork MA, Blaivas M, Rubenfire M, Martinez FJ. Unexplained exertional limitation: characterization of patients with a mitochondrial myopathy. Am J Respir Crit Care Med. 2001;164(3):425-32.

12. Flaherty KR, White ES, Gay SE, Martinez FJ, Lynch JP, 3rd. Timing of lung transplantation for patients with fibrotic lung diseases. Semin Respir Crit Care Med. 2001;22(5):517-32.

13. Saint S, Flaherty KR, Abrahamse P, Martinez FJ, Fendrick AM. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy. Clin Ther. 2001;23(3):499-512.

14. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, Jain A, Strawderman RL, 3rd, Paine R, Flint A, Lynch JP, 3rd, Martinez FJ. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J. 2002;19(2):275-83.

15. Langa KM, Fendrick AM, Flaherty KR, Martinez FJ, Kabeto MU, Saint S. Informal caregiving for chronic lung disease among older Americans. Chest. 2002;122(6):2197-203.

16. Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, Murray S, Thannickal VJ, Kazerooni EA, Gross BH, Lynch JP, 3rd, Martinez FJ. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167(10):1410-5.

17. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP, 3rd, Martinez FJ. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(5):543-8.

18. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, Mumford JA, Murray S, Flint A, Lynch JP, 3rd, Martinez FJ. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003;58(2):143-8. PMCID: PMC1746568.


19. Kim KK, Flaherty KR, Long Q, Hattori N, Sisson TH, Colby TV, Travis WD, Martinez FJ, Murray S, Simon RH. A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Mol Med. 2003;9(1-2):52-6. PMCID: PMC1430380.

20. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP, 3rd, Martinez FJ. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(9):1084-90.

21. Tan BB, Flaherty KR, Kazerooni EA, Iannettoni MD, American College of Chest P. The solitary pulmonary nodule. Chest. 2003;123(1 Suppl):89S-96S.

22. White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res. 2003;9(2):853-60.

23. Choi ES, Jakubzick C, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, Hogaboam CM. Enhanced monocyte chemoattractant protein-3/CC chemokine ligand-7 in usual interstitial pneumonia. Am J Respir Crit Care Med. 2004;170(5):508-15.

24. Flaherty KR, King TE, Jr., Raghu G, Lynch JP, 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170(8):904-10.

25. Jakubzick C, Choi ES, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Toews GB, Colby TV, Travis WD, Joshi BH, Puri RK, Hogaboam CM. Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia. Am J Pathol. 2004;164(6):1989-2001. PMCID: PMC1615781.

26. Jakubzick C, Choi ES, Kunkel SL, Evanoff H, Martinez FJ, Puri RK, Flaherty KR, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, Hogaboam CM. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J Clin Pathol. 2004;57(5):477-86. PMCID: PMC1770295.

27. Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP, 3rd. Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin Pharmacother. 2004;5(8):1671-86.

28. Flaherty KR, Hunninghake GG. Smoking: an injury with many lung manifestations. Am J Respir Crit Care Med. 2005;172(9):1070-1.

29. Fukuoka J, Franks TJ, Colby TV, Flaherty KR, Galvin JR, Hayden D, Gochuico BR, Kazerooni EA, Martinez F, Travis WD. Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases. Am J Surg Pathol. 2005;29(7):948-54.

30. Kocheril SV, Appleton BE, Somers EC, Kazerooni EA, Flaherty KR, Martinez FJ, Gross BH, Crofford LJ. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum. 2005;53(4):549-57.

31. Lama VN, Murray S, Mumford JA, Flaherty KR, Chang A, Toews GB, Peters-Golden M, Martinez FJ. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-


lung transplant recipients. Am J Respir Crit Care Med. 2005;172(3):379-83. PMCID: PMC2718475.

32. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Jr., Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK, Group IPFS. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963-7.

33. Thannickal VJ, Flaherty KR, Hyzy RC, Lynch JP, 3rd. Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2005;10(4):707-27.

34. Attili AK, Kazerooni EA, Gross BH, Flaherty KR, Martinez FJ. Thoracic lymph node enlargement in usual interstitial pneumonitis and nonspecific-interstitial pneumonitis: prevalence, correlation with disease activity and temporal evolution. J Thorac Imaging. 2006;21(4):288-92.

35. Choi ES, Pierce EM, Jakubzick C, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Moore BB, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, Hogaboam CM. Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia. J Clin Pathol. 2006;59(1):28-39. PMCID: PMC1860265.

36. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB, Martinez FJ. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;174(7):803-9. PMCID: PMC2648064.

37. Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther. 2006;4(1):101-24.

38. White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW, Hogaboam CM, Flaherty KR, Martinez FJ, Kontos CD, Toews GB. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med. 2006;173(1):112-21. PMCID: PMC1434700.

39. Chang AC, Chan KM, Lonigro RJ, Lau CL, Lama VN, Flaherty KR, Florn R, Pickens A, Murray S, Martinez FJ, Orringer MB. Surgical patient outcomes after the increased use of bilateral lung transplantation. J Thorac Cardiovasc Surg. 2007;133(2):532-40.

40. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Jr., Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Muller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network I. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-43. PMCID: PMC2094133.

41. Flaherty KR, Andrei AC, King TE, Jr., Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, Gay SE, Gross BH, Kazerooni EA, Knapp R, Louvar E, Lynch D, Nicholson AG, Quick J, Thannickal VJ, Travis WD, Vyskocil J, Wadenstorer FA, Wilt J, Toews GB, Murray S, Martinez FJ. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007;175(10):1054-60. PMCID: PMC1899268.

42. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2007;132(5):1652-8.


43. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Evanoff H, Flaherty KR, Martinez FJ, Toews GB, Hogaboam CM. Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21. Eur Respir J. 2007;29(6):1082-93.

44. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ, Hogaboam CM. Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol. 2007;170(4):1152-64. PMCID: PMC1829450.

45. Attili AK, Kazerooni EA, Gross BH, Flaherty KR, Myers JL, Martinez FJ. Smoking-related interstitial lung disease: radiologic-clinical-pathologic correlation. Radiographics. 2008;28(5):1383-96; discussion 96-8.

46. Flaherty KR. High-resolution computed tomography and the many faces of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(4):367-8.

47. Han MK, Murray S, Fell CD, Flaherty KR, Toews GB, Myers J, Colby TV, Travis WD, Kazerooni EA, Gross BH, Martinez FJ. Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J. 2008;31(6):1183-8.

48. Huang SK, Myers JL, Flaherty KR. The role of lung biopsy in the diagnosis and mangement of idiopathic interstitial pneumonia. Expert Opin Med Diagn. 2008;2(2):183-90.

49. Huang SK, Wettlaufer SH, Hogaboam CM, Flaherty KR, Martinez FJ, Myers JL, Colby TV, Travis WD, Toews GB, Peters-Golden M. Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. Am J Respir Crit Care Med. 2008;177(1):66-74. PMCID: PMC2176116.

50. Hyzy RC, Travis WD, Hanna E, Lyon-Callo S, Flaherty KR, Rosenman KD. Slow-onset asthma deaths have more eosinophils and health care utilization than rapid-onset deaths. Respir Med. 2008;102(12):1819-26.

51. Meneghin A, Choi ES, Evanoff HL, Kunkel SL, Martinez FJ, Flaherty KR, Toews GB, Hogaboam CM. TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol. 2008;130(5):979-92.

52. Muro AF, Moretti FA, Moore BB, Yan M, Atrasz RG, Wilke CA, Flaherty KR, Martinez FJ, Tsui JL, Sheppard D, Baralle FE, Toews GB, White ES. An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(6):638-45. PMCID: PMC2267338.

53. Travis WD, Hunninghake G, King TE, Jr., Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Muller NL, Nicholson AG, Raghu G, Selman M, Wells A. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008;177(12):1338-47.

54. Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, Colby TV, Murray S, Toews GB, Martinez FJ, Flaherty KR. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(5):402-7. PMCID: PMC2648909.

55. Flaherty KR. Clinical year in review IV: Pediatric pulmonary and critical care, cystic fibrosis, asthma, and pleural disease. Proc Am Thorac Soc. 2009;6(6):506-11.


56. Flaherty KR. Idiopathic pulmonary fibrosis: the importance of qualitative and quantitative phenotyping. Imaging Decisions. 2009;13:18-23.

57. Huang SK, Myers JL, Flaherty KR. Diagnosing Idiopathic Interstitial Pneumonias: Utility of Surgical Lung Biopsy. Eur Respir Monograph. 2009;46:24-35.

58. Joshi AD, Fong DJ, Oak SR, Trujillo G, Flaherty KR, Martinez FJ, Hogaboam CM. Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2009;179(8):705-16.

59. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschewski M, Rottoli P, Muller-Quernheim J. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(8):717-23.

60. Schmidt SL, Sundaram B, Flaherty KR. Diagnosing fibrotic lung disease: when is high-resolution computed tomography sufficient to make a diagnosis of idiopathic pulmonary fibrosis? Respirology. 2009;14(7):934-9.

61. Ware LB, Eisner MD, Flaherty KR. Clinical year in review II: Sepsis, mechanical ventilation, occupational and environmental lung disease, and sleep. Proc Am Thorac Soc. 2009;6(6):494-9.

62. Clark BJ, Flaherty KR. Clinical year in review III: pulmonary rehabilitation, respiratory health effects of smoking, genetics of lung disease, and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2010;7(5):312-7.

63. Fell CD, Martinez FJ, Liu LX, Murray S, Han MK, Kazerooni EA, Gross BH, Myers J, Travis WD, Colby TV, Toews GB, Flaherty KR. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181(8):832-7. PMCID: PMC2854332.

64. Han MK, Swigris J, Liu L, Bartholmai B, Murray S, Giardino N, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Flaherty K, Martinez FJ. Gender influences Health-Related Quality of Life in IPF. Respir Med. 2010;104(5):724-30. PMCID: PMC2862780.

65. Idiopathic Pulmonary Fibrosis Clinical Research N, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620-8. PMCID: PMCID in process.

66. Phillips K, Flaherty KR, Matteson EL, Bongartz T, Bathon J, Brown KB, Dellaripa PF. Interstitial Lung Disease in Rheumatoid Arthritis. Curr Rheumatol Rev. 2010;6:120-6.

67. Schmidt SL, Flaherty KR. Clinical year in review I: interstitial lung disease, pulmonary vascular disease and venous thromboembolism, diagnostic imaging, and lung cancer. Proc Am Thorac Soc. 2010;7(5):297-304.

68. Swigris JJ, Brown KB, Flaherty KR. The Idiopathic Interstitial Pneumonias and Connective Tissue Disease-Associated Interstitial Lung Disease. Curr Rheumatol Rev. 2010;6:91-8.

69. Trujillo G, Meneghin A, Flaherty KR, Sholl LM, Myers JL, Kazerooni EA, Gross BH, Oak SR, Coelho AL, Evanoff H, Day E, Toews GB, Joshi AD, Schaller MA, Waters B, Jarai G, Westwick J, Kunkel SL, Martinez FJ, Hogaboam CM. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med. 2010;2(57):57ra82. PMCID: PMC3235647.

70. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE,


McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Eng J Med. 2011;365(8):689-98.

71. Miller MA, Arndt JL, Konkle MA, Chenoweth CE, Iwashyna TJ, Flaherty KR, Hyzy RC. A polyurethane cuffed endotracheal tube is associated with decreased rates of ventilator-associated pneumonia. J Crit Care. 2011;26(3):280-6.

72. Oak SR, Murray L, Herath A, Sleeman M, Anderson I, Joshi AD, Coelho AL, Flaherty KR, Toews GB, Knight D, Martinez FJ, Hogaboam CM. A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One. 2011;6(6):e21253. PMCID: PMC3119674.

73. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Jr., Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ, ATS ERS JRS ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.

74. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-87.

75. Schmidt SL, Flaherty KR. Clinical year in review I: interstitial lung disease, occupational and environmental lung disease, education of residents and fellows, and pediatrics. Proc Am Thorac Soc. 2011;8(5):389-97.

76. Flaherty KR, Herridge MS. Clinical year in review II: Lung cancer, sleep apnea, interventional pulmonary/pleural disease, cystic fibrosis. Proc Am Thorac Soc. 2011;8(5):398-403.

77. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chughtai AR, Lagstein A, Myers JL, Murray S, Toews GB, Martinez FJ, Flaherty KR. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J. 2011;38(1):176-83.

78. Kunisaki KM, Niewoehner DE, Connett JE; COPD Clinical Research Network. Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study. Am J Resp Crit Care Med. 2012;185(3)286-90.

79. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Resp Crit Care Med. 2012;185(10):1044-8.

80. Noth I, Anstrom KJ, Calvert SB, de Andreade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA; for the Idiopathic Pulmonary Fibrosis Clinical Research Network. A Placebo-controlled randomized trial of warfarin in Idiopathic Pulmonary Fibrosis. Am J Resp Crit Care Med 2012;186(1):88-95.

81. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;336(21):1968-77.


82. Naik PK, Bozyk PD, Bentley JK, Popova AT, Birch CM, Wilke CA, Fry CD, White ES, Sisson TH, Tayob N, Carnemolla B, Orecchia P, Flaherty KR, Hershenson MB, Murray S, Martinez FJ, Moore BB; for the COMET Investigators. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012 Dec 15;303(12):L1046-56.

83. Han MK, Bach DS, Hagan P, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ: For the IPFnet Investigators. Right ventricular dysfunction predicts exercise capacity improvement in pulmonary fibrosis. Chest Accepted December 1, 2012.

84. Rahgu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O’Riordan TG, and the ARTEMIS IPF investigators. Treatment of idiopathic pulmonary fibrosis with Abrisentan, a selective antagonist of the endothelin A receptor: A randomized trial. Annals of Internal Medicine Accepted February 4, 2013.

Non-Peer-Reviewed Publications

1999 Lynch III JP, Flaherty K, Martinez FJ. Ventilator associated Pseudomonas aeruginosa pneumonia. Oschner Clinic Report on Serious Infections 1999; 11: 1-11.

2000 Flaherty KR, Martinez FJ. The role of pulmonary function testing in pulmonary fibrosis. Curr Opin Pulm Med 2000; 6: 404-410.

2001 Flaherty KR, Martinez FJ. Lung volume reduction surgery for emphysema. Clin Chest Med 2000; 21: 819-848.

2002 Alhamad EH, Gay SE, Flaherty KR, Martinez FJ. Evaluating chronic dyspnea: A step-wise approach. J Respir Dis 2001; 22: 79-88.

2003 Lynch III JP, White ES, Flaherty KR. Corticosteroids in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2001; 7: 298-308.

2004 Flaherty KR, Martinez FJ, Travis WD, Lynch III JP. Nonspecific interstitial pneumonia (NSIP). Semin Respir Crit Care Med 2001; 22:423-433.

2005 Lynch III JP, Wurfel M, Flaherty KR, White E, Martinez FJ, Travis WD, Raghu G. Usual interstitial pneumonia. Semin Respir Crit Care Med 2001; 22: 357-385.

2006 Flaherty KR, White ES, Gay SE, Martinez FJ, Lynch III JP. Timing of lung transplantation for patients with fibrotic lung diseases. Semin Respir Crit Care Med 2001; 22: 517-531.

2007 Martinez FJ, Flaherty KR, Iannettoni MD. Lung volume reduction surgery for emphysema. Chest Surg Clin N Am 2003; 13: 669-685.

2008 Flaherty KR, Martinez FJ. Cigarette smoking in interstitial lung disease: concepts for the internist. Med Clin N Am 2004; 88:1643-1653.

2009 Martinez FJ, Flaherty KR. Pulmonary function testing in idiopathic interstitial pneumonias. Am Thorac Soc. 2006 Jun; 3(4):315-21.


2010 Flaherty KR, Martinez FJ. Nonspecific interstitial pneumonia. Semin Respir Crit Care Med. 2006; 27(6):652-658

Articles Submitted for Publication

Peer Reviewed

1. Ohtsuka T, Flaherty KR, Lin J, Lama, VN, Reddy RM, Orringer MB, Chan KM, Change AC. Increasing pulmonary artery pressure during the transplantation waiting period is associated with higher mortality following lung transplantation in patients with pulmonary fibrosis. Submitted

2. Flaherty KR, Fell C, Aubry M, Brown KK, Colby TV, Franks T, Gross BG, Hansell DM, Hunninghake G, Kazerooni EA, Kim DS, King TE, Kitachi M, Lynch D, Myers J, Nagai S, Nicholson AG, Poletti V, Raghu G, Selman M, Toews GB, Travis WT, Wells AU, Vassallo R, Martinez FJ. Smoking related indiopathic interstitial pneumonia: Results of an international workshop. Submitted

3. Rahgu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O’Riordan TG, and the ARTEMIS IPF investigators. Treatment of idiopathic pulmonary fibrosis with Abrisentan, a selective antagonist of the endothelin A receptor: A randomized trial. Submitted.

4. Shelley L. Schmidt MD, Nabihah Tayob MS, Meilan K. Han MD, MS, Christopher Zappala MD, Dolly Kervitsky CRT, Susan Murray ScD, Galen B. Toews MD, Athol U. Wells MD, Kevin K. Brown MD, Fernando J. Martinez MD, MS and Kevin R. Flaherty MD, MS. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Submitted.


Non Peer Reviewed

Chapters in Books

1. Lynch III JP, Flaherty KR, Martinez FJ. Pseudomonas aeruginosa ventilator-associated pneumonia. In: Pankey GA, ed. Serious Hospital Infections. A Millenium Compilation. Newtown, Handbooks in Health Care Co., 2000, pp 157-180.

2. Flaherty KR, Martinez FJ, Chenoweth CE, Lynch III JP. The role of Pseudomonas aeruginosa in community-acquired pneumonia. In: Rello J, Leeper Jr. K (eds). Severe Community Acquired Pneumonia. Boston. Kluwer Academic Publishers, 2001, pp75-103.

3. Flaherty KR, Weisman I, Zeballos J, Martinez FJ. The role of cardiopulmonary exercise testing for patients with suspected metabolic myopathies and other neuromuscular disorders. In: Weisman I, Zeballos RJ, eds. Progress in Respiratory Research, Volume 32: Clinical Exercise Testing. Basil, Switzerland. Karger 2002, pp242-253.

4. Gay SE, Weisman I, Flaherty KR, Martinez FJ. Cardiopulmonary exercise testing in unexplained dyspnea. In: Weisman I, Zeballos RJ, eds. Progress in Respiratory Research, Volume 32: Clinical Exercise Testing. Basil, Switzerland. Karger 2002, pp 81-88.

5. Martinez FJ, Gay SE, Flaherty KR. Management of non-bronchiectatic chronic obstructive pulmonary disease. In: Maurer J, ed. Management of Non-neoplastic Advanced Lung Disease. New York, NY. Marcel Dekker, 2003, pp. 271-337.

6. Martinez FJ, Flaherty KR, Travis WD, Lynch III JP. Nonspecific interstitial pneumonia. In: Lynch III JP, ed. Idiopathic Pulmonary Fibrosis. New York, NY. Marcel Dekker, 2004, pp. 101-136.

7. Zisman DA, Flaherty KR, Kazerooni EA, Martinez FJ, Lynch III JP. Role of high-resolution thin section computed tomographic scanning. In: Lynch III JP, ed. Idiopathic Pulmonary/ Fibrosis. New York, NY. Marcel Dekker, 2004, pp. 167-236.

8. Flaherty KR, Martinez FJ. The role of computed tomography in emphysema and lung volume reduction surgery. In: Lipson DA, Van Beek EJR, eds. Functional Lung Imaging. Boca Raton, FL. Taylor & Francis, 2005, pp. 431-451.

9. Subramanian I, Flaherty KR, Martinez FJ. Pulmonary function testing in sarcoidosis. In: Baughman RP, ed. Sarcoidosis. New York, NY. Marcel Dekker. In press

10. Martinez FJ, Hogaboam CM, Choi ES, Flaherty KR, Thannickal VJ. Interstitial lung disease: Idiopathic pulmonary fibrosis. In: Laurent GJ, Shapiro SD, eds. Encyclopedia of Respiratory Medicine. Oxford. Elsevier Limited. Vol. 1, 2006, pp. 440-447.

11. Fields WB, Flaherty KR. Interstitial Lung Disease. In: Williams MV, Flanders SA, Whitcomb WF, Cohn SL, Michota FA, Holman R, Gross R, Merli GJ, eds. Comprehensive Hospital Medicine: An Evidence-Based Approach Philadelphia, PA. Saunders Elsevier, 2007, pp. 374-381.

12. Flaherty KR. Nonspecific Interstitial Pneumonitis (NSIP). In: Lynch II JP, ed. Interstitial Pulmonary and Bronchiolar Disorders. New York, NY. Informa Healthcare, 2008, pp.365-378.

13. Martinez FJ, Flaherty KR. Non-specific interstitial pneumonia. In: Schwartz M, King Jr. TE, eds. Interstitial Lung Disease, 5th edition. Shelton, CT. People's Medical Publishing House. 2010, 99. 945-960.


14. Flaherty KR, Martinez FJ. Non-specific interstitial pneumonia. In: Baughman R, du Bois R, eds. Diffuse Lung Disease: A Practical Approach, 2 nd edition . New York, NY. Springer Science + Business Media. 2012, 11. 195-216.

Other Media

1. Martinez FJ, Flaherty KR. Diagnosis of Interstitial Lung Disease. Pulmonary and Critical Care Update. American College of Chest Physicians. 2004; Volume 18, Lesson 3. http://www.chestnet.org/education/online/pccu/vol18/\

2. Zisman DA, Flaherty KR. Interstitial Pulmonary Fibrosis. (PIER) Physicians' Information and Education Resource on-line database. American College of Physicians. 2006. http://pier.acponline.org/physicians/diseases/d169

3. Flaherty KR “Nonspecific Interstitial Pneumonia,” in Rose B (ed.), Up-to-Date in Pulmonary and Critical Care Medicine, 2012, Wellesley, MA (CD-ROM).

Abstracts

1. Flaherty K, Christensen P, Iannettoni M, Meldrum K, Kazerooni E, Ojo-Clark T, Martinez F. Thirty-six Month Follow up of Patients Following Lung Volume Reduction Surgery (LVRS). Am J Respir Crit Care Med 1999; 159: A923.

2. Flaherty K, Zisman D, Wald J, Bria W, Foss K, True M, Weissmann I, Zeballos J, Martinez F. Tidal Flow Volume Loop Analysis During Exercise in Mitochondrial Myopathy (MM). Am J Respir Crit Care Med 1999; 159: A419.

3. Flaherty K, Zisman D, Strawderman R, Lynch III JP, Kazerooni E, Toews G, Hariharan K, Gross B, Spizarny D, Cascade P, Flint A, Martinez F. Serial HRCT Improves Ability to Follow Patients with IPF During Therapy. Am J Respir Crit Care Med 1999; 159: A50.

4. Flaherty K, Lynch III JP, Toews G, Hariharan K, Strawderman R, Strieter R, Kazerooni E, Flint A, Martinez F. High Dose versus Low Dose Corticosteroids in the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Am J Respir Crit Care Med 1999; 159: A50

5. Flaherty K, A Flint, T Colby, G Toews, JP Lynch III, K Hariharan, F Martinez. Intrapatient variation of diagnosis obtained by open lung biopsy in patients with interstitial lung disease. Eur Respir J 1999; 14:S30 A273.

6. Martinez F, Flaherty K, Flint A, Colby T, Lynch JP III, Hariharan K, Toews G. Survival and response to therapy in patients with NSIP versus UIP. Eur Respir J 1999; 14:S30 A272.

7. Flaherty K , Martinez F, Peters-Golden M, Lynch JP III, Hariharan K, Kazerooni E, Flint A, Gross B, and Toews G. Zileuton versus Azathioprine: A randomized controlled trial of novel therapy for idiopathic pulmonary fibrosis. Eur Respir J 1999; 14:S30 A103.

8. Flaherty K, Kazerooni E, Christensen P, Paine R, Curtis J, Bria W, Iannettoni M, Martinez F. Failure of Quantitative Emphysema Defined by HRCT to Correlate with Bronchoreversibility. Chest 1999; 116:276S.

9. Martinez F, Flaherty K, Flint A, Colby T, Lynch III JP, Hariharan K, Toews G. Survival and response to therapy in patients with NSIP versus UIP. Eur Respir J 1999; 14:272S.

10. Flaherty K, Flint A, Colby T, Toews G, Lynch JP III, Hariharan K, Martinez F. Intrapatient variation of diagnosis obtained by open lung biopsy in patients with fibrotic lung disease. Eur Respir J 1999; 14:273S.


http://pier.acponline.org/physicians/diseases/d169

http://www.chestnet.org/education/online/pccu/vol18/%5C

11. Flaherty K, Martinez F, Peters-Golden M, Lynch JP III, Hariharan K, Kazerooni E, Flint A, Gross B, Toews G. Zileuton versus azathioprine: A randomized controlled trial of novel therapy for idiopathic pulmonary fibrosis (IPF). Eur Respir J 1999; 14:103S.

12. Kazerooni E, Flaherty K, Gross G, Toews G, Lynch JP III, Flint A, Colby T, Travis WD, Martinez F. Semiquantitative HRCT in NSIP vs UIP. Am J Respir Crit Care Med 2000; 161: A527.

13. Travis WD, Flaherty K, Colby TV, Flint A, Toews G, Lynch JP III, Kazerooni E, Gross B, Martinez F. Histologic patterns of interstitial pneumonia in patients with surgical lung biopsies of multiple lobes. Am J Respir Crit Care Med 2000; 161: A526.

14. Flaherty K, Kazerooni E, Iannettoni M, Ojo T, Bria W, Martinez F for the National Emphysema Treatment Trial (NETT). Quality of life and functional deterioration in patients with emphysema is independent of change in emphysema volume by HRCT. Am J Respir Crit Care Med 2000; 161: A787.

15. Flaherty K, Colby T, Travis T, Flint A, Toews G, Lynch JP III, Kazerooni E, Gross B, Martinez F. Survival in patients with histologic subsets of NSIP versus UIP. Am J Respir Crit Care Med 2000; 161: A708.

16. Kazerooni E, Flaherty K, Gross B, Toews G, Lynch JP III, Flint A, Colby T, Travis WD, Martinez F. Comparison of semiquantitative HRCT scoring in patients versus UIP at initial presentation. Accepted by the Society of Thoracic Radiology,

17. Flaherty KR, Toews GB, Lynch III JP, Flint A, Colby TV, Travis WD, Martinez FJ. Rate of change in pulmonary function in patients with UIP and NSIP. Eur Respir J 2000; accepted for poster discussion at European Respiratory Society World Congress.

18. Martinez FJ, Flaherty KR, Kazerooni EA, Curtis JL, Paine III R, Iannettoni MD. Four-year follow-up after bilateral lung volume reduction surgery. Eur Respir J 2000; accepted for oral presentation at European Respiratory Society World Congress.

19. Flaherty KR, Kazerooni EA, Gross B, Toews GB, Lynch III JP, Flint A, Colby TV, Travis WD, Martinez FJ. Rate of change in semiquantitative high resolution computed tomography (HRCT) scores in patients with UIP and NSIP. Eur Respir J 2000; accepted for oral presentation at European Respiratory Society World Congress.

20. Gay S, Flaherty K, Kazerooni E, Iannettoni M, Bria W, Martinez FJ. Four year follow-up of patients that underwent bilateral lung volume reduction surgery (LVRS). Am J Respir Crit Care Med 2001; 163: A487.

21. Gay S, Flaherty K, Alhamad E, Kazerooni E, Iannettoni M, Bria W, Martinez FJ. Six minute walk distance (6MWD) in COPD: Role of emphysema volume by helical CT. Am J Respir Crit Care Med 2001; 163: A912

22. Bria W, Alhamad E, Flaherty K, Kazerooni E, Iannettoni M, Gay S, Martinez FJ. Difference in COPD patients with vs without severe emphysema quantified by helical CT. Am J Respir Crit Care Med 2001; 163: A912.

23. Alhamad E, Kazerooni E, Flaherty K, Iannettoni M, Gay S, Bria W, Martinez FJ. Survival in COPD is dependent on emphysema volume by helical CT. Am J Respir Crit Care Med 2001; 163: A909

24. Flaherty K, Kazerooni E, Toews G, Colby T, Travis WD, Gross B, Flint A, Lynch III JP, Gay S, Martinez FJ. Change in pulmonary function and semiquantitative HRCT scores in patients with UIP and NSIP. Am J Respir Crit Care Med 2001; 163: A983

25. Beekman K, Flaherty KR, True M, Foss CM, Martinez FJ. Lack of differential outcomes in circular versus linear hallwalks. Am J Respir Crit Care Med 2001; 163: A625


26. Flaherty K, Colby T, Travis W, Toews G, Flint A, Gay S, Strawderman R, Jain A, Lynch III JP, Martinez FJ. Differential presence of fibroblastic foci in usual interstitial pneumonia patients with or without connective tissue disease Am J Respir Crit Care Med 2001; 163: A983

27. Cheng D, Kazerooni EA, Alhamad EH, Flaherty KR, Martinez FJ. Predictors of survival in patients with emphysema, including severity of emphysema using quantitative helical CT, functional and physiologic parameters. Submitted to Radiological Society of North America, 2001

28. Thwaite EL, Kazerooni EA, Gross BH, Flaherty KR, Toews GB, Martinez FJ. Accurary and interobserver agreement in distinguishing between usual interstitial pneumonitis and non-specific interstitial pneumonitis on HRCT: Results in 96 patients. Submitted to Radiological Society of North America, 2001

29. Martinez FJ, Flaherty KR, Travis WD, Colby TV, Kazerooni EA, Gross BH, Jain A, Strawderman III RL, Flint A, Lynch III JP, Toews GB. Quantifying risk of mortality in idiopathic interstitial pneumoni (IIP). Eur Respir J 2001; 18: Suppl. 33, 149s.

30. Flaherty KR, Kazerooni EA, Gross BH, Toews GB, Thwaite EL, Lynch III JP, Colby TV, Travis WD, Martinez FJ. Prognostic value of a high resolution computed tomograph (HRCT) diagnosis of usual interstitial pneumonia (UIP) compared to a histologic diagnosis of UIP. Eur Respir J 2001; 18: Suppl. 33, 150s.

31. Flaherty KR, Thwaite E, Kazerooni E, Gross B, Toews GB, Colby T, Travis WD, Mumford J, Murray S, Flint A, Lynch III JP, Martinez FJ. Radiologic vs histologic diagnosis in UIP and NSIP: Clinical implications. Am J Respir Crit Care Med 2002; 165: A138.

32. Alhamad E, Bach D, Kazerooni E, Flaherty KR, Gay S, Ojo T, Martinez FJ. Survival is worse in COPD patients with right heart abnormalities on echocardiography. Am J Respir Crit Care Med 2002; 165: A445.

33. Martinez FJ, Flaherty KR, Travis WD, Colby TV, Kazerooni E, Lynch III JP, Toews GB. Clinical-radiographic-pathologic diagnosis in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2002; 165: A138.

34. Gay SE, Alhamad E, Bach D, Kazerooni E, Flaherty KR, Martinez FJ. Survival in COPD patients <65 years of age is dependent on emphysema volume by HRCT. Am J Respir Crit Care Med 2002; 165: A656.

35. Fukuoka J, Colby TV, Leslie KO, Saito Y, Flaherty KR, Martinez FJ. Small airway pathology in never smokers with IPF. Am J Respir Crit Care Med 2002; 165: A139.

36. Lama V, Arenberg D, Flaherty K, Moore B, Kazerooni E, Standiford T, Toews G, Martinez FJ. Macrophage migration inhibitory factor (MIF) in pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165: A172.

37. Martinez FJ, Flaherty KR, Travis WD, Colby TV, Kazerooni EA, Lynch III JP, Toews GB. Pathologist inter-rater agreement improves over time in idiopathic interstitial pneumonia (IIP). Eur Respir J 2002; 20: Suppl. 38, 62s.

38. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Long Q, Murray S, Lynch III JP, Martinez FJ. Clinical-radiologic-pathologic diagnosis in idiopathic interstitial pneumonia (IIP). Eur Respir J 2002; 20: Suppl. 38, 61s.

39. Flaherty KR, Lama VN, King Jr. TE, Raghu G, Lynch III JP, Travis WD, Colby TV, Kazerooni EA, Gross BH, Long Q, Murray S, Toews GB, Gay SE, Martinez FJ. Clinical-radiographic-pathologic diagnosis in idiopathic interstitial pneumonia (IIP). Am


J Respir Crit Care Med 2003; 167:A299.40. Lama VN, Flaherty KR, Colby TV, Travis WD, Toews GB, Lynch III JP, Kazerooni EA,

Gross BH, Murray S, Mumford JA, True M, Gay SE, Martinez FJ. Exercise induced desaturation and mortality in usual interstitial pneumonia (UIP). Am J Respir Crit Care Med 2003; 167:A300.

41. Lama VN, Flaherty KR, Travis WD, Colby TV, Toews GB, Lynch III JP, Kazerooni EA, Gross BH, Murray S, Mumford JA, True M, Gay SE, Martinez FJ. Predictors of exercise induced desaturation in usual interstitial pneumonia (UIP). Am J Respir Crit Care Med 2003; 167:A986.

42. Flaherty KR, Kazerooni EA, Mumford JA, Murray S, Gay SE, Martinez FJ. Emphysema quantity determined by high resolution computed tomography predicts bronchodilator response to albuterol. Am J Respir Crit Care Med 2003; 167:A80.

43. Jakubzick C, Kunkel SL, Martinez FJ, Flaherty KR, Puri RK, Toews GB, Colby TV, Travis WD, Lynch III JP, Hogaboam CM. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 167:A840.

44. Flaherty KR, Colby TV, Travis WD, Toews GB, Martinez FJ. Comparison of fibroblastic foci scoring systems in usual interstitial pneumonia (UIP). Eur Respir J 2003; 22: Suppl. 45, 376s.

45. Jakubzick C, Choi ES, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Toews GB, Colby TV, Travis WD, Hogaboam CM. Enhanced CCL7 expression in usual interstitial pneumonia. Am J Respir Crit Care Med 2004; 169:A706.

46. Flaherty KR, Long Q, Murray S, Travis WD, Colby TV, Lama V, Gay SE, Toews GB, Martinez FJ. Baseline quality of life is similar in patients with usual interstitial pneumonia is similar compared to patients with nonspecific interstitial pneumonia. Am J Respir Crit Care Med 2004; 169:A778.

47. Flaherty KR, King TE, Raghu G, Kazerooni EA, Gross BH, Travis WD, Colby TV, Lynch III JP, Long Q, Murray S, Gay SE, Lama VN, Thannickal VJ, Toews GB, Martinez FJ. A confident clinical and radiographic diagnosis of usual interstitial pneumonia or nonspecific interstitial pneumonia is associated with a higher likelihood of finding histologic UIP or NSIP on biopsy. Am J Respir Crit Care Med 2004; 169:A706.

48. Gay SE, Kazerooni EA, Cheng D, Flaherty KR, Mumford JA, Murray S, Curtis JL, Lama VN, Christensen PJ, Martinez FJ. The predictive value of exercise induced desaturation on mortality in patients with severe COPD. Am J Respir Crit Care Med 2004; 169:A773.

49. Lama VN, Mumford JA, Murray S, Flaherty KR, Gay SE, Clark Ojo T, Hyzy RC, Toews GB, Martinez FJ. Role of potential bronchiolitis obliterans syndrome stage (BOS 0-p). Am J Respir Crit Care Med 2004; 169:A268.

50. Lama VN, Mumford JA, Murray S, Peters-Golden M, Flaherty KR, Gay SE, Clark Ojo T, Hyzy RC, Toews GB, Chang A, Polidori DJ, Iannettoni MD, Martinez FJ. Validating predictive utility of the bronchiolitis obliterans syndrome designation. Am J Respir Crit Care Med 2004; 169:A270.

51. Lama VN, Flint A, Smith L, Martinez FJ, Peters-Golden M, Toews GB, Thannickal VJ. Role and origin of myofibroblasts in the pathogenesis of bronchiolitis obliterans in lung transplant recipients. Am J Respir Crit Care Med 2004; 169:A504.

52. Pierce BM, Carpenter K, Jakubzick, Kunkel SL, Flaherty KR, Martinez FJ, Hogaboam CM. A novel murine model of human IIP. Am J Respir Crit Care Med 2004; 169:A862.


53. Gay SE, Flaherty KR, Mumford J, Kazerooni EA, Murray S, Martinez FJ. Decreased body mass index in COPD is associated with quantity of emphysema. Eur Respir J 2004; 24: Suppl. 48, 31s.

54. Flaherty KR, Kazerooni EA, Gross BH, Colby TV, Travis WD, Dahlgren D, Toews GB, Lama VN, Martinez FJ. The presence of desaturation during ambulation is an important marker of subsequent mortality in patients with early UIP. Eur Respir J 2004; 24: Suppl. 48, 55s.

55. Flaherty KR, Peters-Golden M, Travis WD, Colby TV, Gross BH, Kazerooni EA, Toews GB, Dahlgren D, Martinez FJ. Zileuton versus azathioprine/prednisone in idiopathic pulmonary fibrosis. Eur Respir J 2004; 24: Suppl. 48, 254s.

56. Gay SE, Kazerooni EA, Flaherty KR, Mumford J, Murray S, Martinez FJ. Change in Inspiratory Capacity (IC) after Bronchodilator in Patients with Emphysema Quantified Computed Tomography (CT). Proceedings of the American Thoracic Society 2005; 2:A259.

57. Fraley C, Martinez FJ, Lama V, Colby T, Travis W, Toews GB, Flint A, Chang A, Flaherty KR. Distance Walking During a Six Minute Walk Test (6MWT) Relative to the Quantity of Desaturation Predicts Mortality in Patients with Idiopathic Pulmonary Fibrosis (IPF). Proceedings of the American Thoracic Society 2005; 2:A316.

58. Martinez FJ, Mumford J, Hoffman E, Criner G, Cook-Granroth J, Robinswood B, Mohsenifar Z, Kazerooni E, Gay S, Flaherty K, Ries A, Kaplan R, Fishman A, Make B, Sciurba F. Women with Severe Emphysema Report Greater Breathlessness and Porer Health Status Than Men. Proceedings of the American Thoracic Society 2005; 2:A401.

59. Flaherty K, Wells A, duBois R, Nicholson A, Lynch D, Wadenstorer F, Vyskocil J, Bassily N, Louvar E, Wilt J, Quick J, Knapp R, Raghu G, King T, Colby T, Travis W, Flint A, Thannickal V, Andrei A, Murry S, Fraley C, Gay S, Toews GB, Martinez FJ. Diagnostic Agreement Between Academic and Community Pulmonologists for Cases of Idiopathic Interstitial Pneumonia (IIP). Submitted to American Thoracic Society 2005; 2:A122

60. Martinez FJ, Hoffman E, Cook-Granroth J, Robinswood B, Mumford, J, Criner G, Fishman A, Gay S, Flaherty K, Make B, Kazerooni E, Sciurba F. Gender differences in the extent and distribution of emphysema. Proceedings of the American Thoracic Society 2005; 2:A257.

61. Flaherty K, Wells A, duBois R, Nicholson, Brown K, Lynch D, Wadenstorer F, Vyskocil J, Bassily N, Louvar E, Wilt J, Quick J, Knapp R, Raghu G, King T, Colby T, Travis W, Flint A, Thannickal V, Andrei A, Murry S, Fraley C, Gay S, Toews GB, Martinez FJ. Diagnostic Agreement Between Academic and Community Radiologists for Cases of Idiopathic Interstitial Pneumonia. Proceedings of the American Thoracic Society 2005; 2:A122.

62. Flaherty K, Wells A, duBois R, Nicholson, Brown K, Lynch D, Wadenstorer F, Vyskocil J, Bassily N, Louvar E, Wilt J, Quick J, Knapp R, Raghu G, King T, Colby T, Travis W, Flint A, Thannickal V, Andrei A, Murry S, Fraley C, Gay S, Toews GB, Martinez FJ. Diagnostic Agreement Between Academic and Community Pathologists for Cases of Idiopathic Interstitial Pneumonia. Proceedings of the American Thoracic Society 2005; 2:A387.

63. Peters-Golden M, Wettlaufer SH, Moore BB, Hogaboam, Flaherty KR, Martinez FJ. Prostaglandin E2 production and responsiveness in lung fibroblasts from patients with


usual and nonspecific interstitial pneumonia. Proceedings of the American Thoracic Society 2005; 2:A209.

64. Martinez FJ, Flaherty KR, Patel MP. Efficacy of telithromycin in Haemophilus influenzae in US patients with acute exacerbations of chronic bronchitis: A pooled analysis. Proceedings of the American Thoracic Society 2005; 2:A401.

65. Choi ES, Pierce E, Meneghin A, Carpenter KJ, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Moore BB, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, Hogaboam CM. Enhanced CC chemokines recptor-7 (CCR&) transcript and protein expression in usual interstitial pneumonia (UIP). Proceedings of the American Thoracic Society 2005; 2:A635.

66. Martinez F, Criner G, Hoffman E, Wise R, Gay S, Flaherty K, Make B, Sciurba F. Spirometric bronchoreversibility (SBR) in emphysema patients. Proceedings of the American Thoracic Society 2005; 2:A650.

67. Martinez FJ, Benditt J, Criner G, Make B, Wise R, Foster G, Tonascia J, Hoffman E, Fishman A, Gay S, Flaherty K, Weinmann G, Sciurba F. Multidimensional index predicts mortality in severe emphysema. Proceedings of the American Thoracic Society 2005; 2:A890.

68. Attili AK, Kazerooni EA, Gross BH, Flaherty KR, Martinez FJ. Thoracic Lymph Node Enlargement in Usual Interstitial Pneumonitis and Non Specific Interstitial Pneumonitis: Prevalence and Correlation with Disease Activity. Presented at the World Congress of Thoracic Imaging 2005.

69. Flaherty KR, Andrei A, Fraley C, Colby TV, Travis WT, Toews GB, Murray S, Martinez FJ. Serial Change in FVC Predicts Survival in IPF Patients without Baseline Desaturation<88% During a Six Minute Walk Test but not in Patients with Baseline Desaturation. Proceedings of the American Thoracic Society 2006; 3: A103.

70. Flaherty KR, Gay SE, Travis WT, Colby TV, Kazerooni EA, Gross BG, Toews GB, Martinez FJ. Advanced Age is Associated with a Diagnosis of IPF Compared to NSIP. Proceedings of the American Thoracic Society 2006; 3: A104.

71. Flaherty KR, Andrei A, Fraley C, Colby TV, Travis WT, Toews GB, Murray S, Martinez FJ. Change in Six Minute Hallwalk Distance Over Time in Patients with Idiopathic Pulmonary Fibrosis. Proceedings of the American Thoracic Society 2006; A103.

72. Chan KM, Chang AC, Lama VN, Lau CL, Gay SE, Ojo TC, Flaherty KR, Hyzy RC, Florn R, Walls C, Berry-Edwards J, Pickens A, Martinez FJ. Double vs single lung transplantation: Single center 15 year results. Proceedings of the American Thoracic Society 2006; 3: A366

73. Meneghin A, Choi ES, O’Connor EC, Evanoff HL, Martinez FJ, Flaherty KR, Toews GB, Hogaboam CM. TLR9 activation promotes chemokines and collagen production in human pulmonary fibroblasts pretreated with Th2 cytokines. Proceedings of the American Thoracic Society 2006; 3: A801

74. Han MK, Flaherty KR, Curtis JL, Saint S, Gay SE, Martinez FJ. Systematic review of antibiotic therapy and Haemophilus influenzae eradication in acute exacerbations of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2006; 3: A841

75. Choi ES, Meneghin A, Jakubzick C, Kunkel SL, Evanoff H, Martinez FJ, Flaherty KR, Toews GB, Colby TV, Kazerooni EA, Gross BH, Travis WD, Puri PK, Hogaboam CM. Idiopathic Interstitial Pneumonia Transbronchial Biopsy (TBB)-Derived Fibroblasts


Exhibit Similar Proliferative and Synthetic Properties Compared with Surgical Lung Biopsy (SLB)-Derived Fibroblasts. Proceedings of the American Thoracic Society 2006; 3: A104

76. Flaherty KR, Brown K, Colby TV, Costabel U, Flint A, Franks T, Gross B, Hansell D, Hunninghake G, Kazerooni E, Kim D, King T, Lynch D, Myers J, Nagai S, Nicholson A, Poletti V, Raghu G, Travis W, Wells A, Martinez FJ. Smoking Related Interstitial Lung Disease – An International Working Group Effort. Presented at the European Respiratory Society Meeting; Munich, Germany; September 2006.

77. Flaherty KR, Andrei A, Fraley C, Gross B, Kazerooni EA, Colby TV, Travis WD, Toews GB, Murray S, Martinez FJ. Impact of baseline desaturation during a six minute walk test (6MWT) on prognostic value of subsequent changes in FVC and DLCO. Presented at the European Respiratory Society Meeting; Munich, Germany; September 2006.

78. Giardino N, Curtis J, Andrei A, Gay S, Criner G, Naunheim K, Benditt J, Make B, Wise R, Murray S, Fishman A, Flaherty KR, Sciurba F, Martinez FJ, and for the NETT Research Group. Baseline anxiety independently predicts functional limitation and reduced health status in severe emphysema. Presented at the European Respiratory Society Meeting; Munich, Germany; September 2006.

79. Attili AK, Kazerooni EA, Gross B, Flaherty K, Colby TV, Myers J, et al. Smoking-Related Interstitial Lung Disease (ILD): A Definition with Radiologic-Clinical-Pathologic Correlation, Presented at the Radiological Society of North America Meeting; McCormick Place, Chicago 2006.

80. Flaherty KR, Brewer GJ, Andrei A, Murray S, Toews GB, Martinez FJ. A phase I/II trial of Tetrathiomolybdate for patients with idiopathic pulmonary fibrosis refractory to previous therapy. Am J Respir Crit Care Med 2007; 175: A497.

81. Han MK, Meneghin A, Flaherty KR, Martinez FJ, Fell C, Toews GB, Thannickal VJ, Colby TV, Travis WD, Kazerooni EA, Gross BH, Hogaboam C. TLR9 and vGPCR expression varies by gender in IPF lung. Am J Respir Crit Care Med 2007; 175: A139.

82. Han, MK, Fell CD, Flaherty KR, Kazerooni EA, Gross BH, Colby TV, Travis WD, Thannickal VJ, Toews GB, Martinez FJ. Gender and Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2007; 175: A146.

83. Fell CD, Liu LX, Baumann C, Kazerooni EA, Gross BH, Travis WD, Colby TV, Murray S, Toews GB, Martinez FJ, Flaherty KR. The Prognostic Value of Serial Cardiopulmonary Exercise Testing in IPF. Am J Respir Crit Care Med 2007; 175: A569.

84. Fell CD, Kazerooni EA, Gross BH, Travis WD, Colby TV, Toews GB, Martinez FJ, Flaherty KR. Serial Measures of Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2007; 175: A145.

85. Han, MK, Flaherty KR, Gender Differences in Serial Pulmonary Function Testing in Idiopathic Pulmonary Fibrosis. European Respitory Society 2007; Abstract No. 253538

86. Xu, Y, Flaherty KR “Whole Lung 3D Texture Classification of Interstitial Lund Diseases in MDCT Images” 93rd Scientific Assembly and Annual Meeting of the Radiological Society of North America 2007 (Accepted)213.

87. Huang SK, Wettlaufer SH, Hogaboam C, Flaherty KR, Martinez FJ, Toews GB, Peters-Golden M. Prostaglandin E2 inhibition of proliferation and collagen synthesis is diminished in fibroblasts from patient with idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2007; 175:A734.


88. Han MK, Fell C, Thannickal V, Martinez, FJ, Flaherty K. Gender Differences in Rate of Deterioration in Desaturation During Six Minute Hallwalk Testing in Patients with Idiopathic Pulmonary Fibrosis. European Respiratory Society 2007; Abstract No.254505.

89. Han MK, Bartholmai B, Flaherty KR, Limper A, Frederick M, Thompson B, Li D, Thannickal VJ, Toews GB, Martinez, FJ. Gender difference in SGRQ in patients with IPF. Am J Respir Crit Care Med 2008;177:A251.

90. Han MK, Bartholmai B, Curtis JL, Limper A, Sciurba FCm Bon JM, Robb RA, Karwoski RA, Frederick M, Thompson B, Li D, Flaherty KR, Schwarz MI, Martinez FJ. Emphysema percent predicts quality of life and symptoms in COPD: An analysis of Lung Tissue Research Consortium patients. Am J Respir Crit Care Med 2008; 177:A520.

91. Han MK, Bartholmai B, Flaherty KR, Limper A, Schwarz MI, Thannickal VJ, Frederick M, Thompson B, Li D, Toews GB, Martinez FJ. Gender differences in emotional function in patients with IPF: A Lung Tissue Research Consortium study. Am J Respir Crit Care Med 2008; 177: A886.

92. Han MK, Curtis JL, Gay SE, Flaherty KR, Kazerooni EA, Martinez FJ. Desaturation area predicts pulmonary artery systolic pressure in patients with emphysema. Am J Respir Crit Care Med 2008: 177: A780.

93. Fell CD, Han MK, Liu L, Martinez FJ, Motika C, Kazerooni EA, Gross BH, Travis WD, Colby TV, Toews GB, Flaherty KR. Clinical predictors of survival in IPF. Am J Respir Crit Care Med 2008; 177: A249.

94. Flaherty KR, Fell CD, Aubry M, Brown KK, Colby TV, Costabel U, duBois, Flint A, Franks T, Gross BH, Hunninghake G, Kazerooni EA, Kim D, King TE, Kitachi M, Lynch D, Nagai S, Nicholson A, Poletti A, Raghu G, Toews GB, Travis WD, Wells A, Vassallo R, Martinez FJ. Can Clinical, Radiographic, and Pathologic Features Discriminate Smoking From Non-smoking Cases of Idiopathic Interstitial Pneumonia (IIP) Am J Respir Crit Care Med 2008; 177: A882.

95. Flaherty KR, Fell CD, Han MK, Myers J, Gross BH, Kazerooni EA, Dahlgren D, Martinez FJ, Toews GB. Longitudinal change in pulmonary function is influenced by baseline value. Am J Respir Crit Care Med 2008; 177: A882.

96. Freeman CM, Martinez FJ, Arenberg DA, Chensue SW, Murphy HS, Meldrum C, Han MK, Flaherty KR, Frederick M, Thompson B, Curtis JL. Lung IL-15 production in COPD correlates with measures of disease severity: a study using LTRC resources. Am J Respir Crit Care Med 2008; 177: A961.

97. Phillips KA, Lama VN, Chang AC, Han MK, Flaherty KR, Gay SE, Ojo TC, Pickens A, Florn R, Walls C, Mahaffey L, Martinez FJ, Chan KM. Development of α1-Antitrypsin deficiency related disease following lung transplantation for emphysema. Am J Respir Crit Care Med 2008; 177: A389.

98. Brown KK, Flaherty KR, Daniels C, Wuyts W, Loyd J, Raghu G, Noth I, Whelan T, Striesand J. Safety and tolerability of GC1008, a human monoclonal antibody against TGFβ, in patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2008; 177: A768.

99. Flaherty KR, Yu X, Guo J, Martinez FJ, Kazerooni EA, Hoffman EA. Computer assisted HRCT analysis of IPF patients detects change in ground glass opacity despite stable forced vital capacity. Eur Respir J 2008;32:603S.

100. Flaherty KR, Martinez FJ, Toews GB, Dahlgren D, Peters-Golden M. 5-Lipoxygenase inhibitor therapy in IPF. Eur Respir J 2008;32:746.


101. Han MK, Bartholmai B, Murray S, Curtis JL, Limper A, Sciurba F, Robb R, Karowski R, Frederick M, Thompson B, Li D, Flaherty KR, Schwarz MI, Martinez FJ. Quantified radiographic measures predict cough and self-reported acute exacerbation frequency in COPD. Am J Respir Crit Care Med 2009;179: A6213.

102. Han MK, Hogaboam CM, Murray S, Flaherty KR, Toews GB, MartinezFJ. Plasma relaxin predicts FVC in IPF. Am J Respir Crit Care Med 2009;179: A3014.

103. Han MK, Bach D, Murray S, Flaherty KR, Toews GB, MartinezFJ. Male gender is associated with pulmonary hypertension in IPF. Am J Respir Crit Care Med 2009;179: A4058.

104. Schmidt S, Nambiar A, Han MK, Myers J, Lagstein A, Flint A, Gross B, Kazerooni EA, Chugtai A, Sundaram B, Toews G, Martinez FJ, Flaherty KR. Does the composite physiology score improve the correlation to the six minute walk test over individual pulmonary function tests in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179: A1116.

105. Ohtani Y, Nambiar A, Schmidt S, Han MK, Kazerooni EA, Myers JL, Gross BH, Flint A, Sundaram B, Inase N, Yoshizawa Y, Toews GB, Martinez FJ, Flaherty KR. Idiopathic nonspecific interstitial pneumonia: Prognostic value of hallwalk distance and changes in physiology. Am J Respir Crit Care Med 2009;179: A1121.

106. Nambiar A, Han MK, Schmidt S, Myers JL, Lagstein A, Flint A, Gross BH, Kazerooni EA, Sundaram B, Chugtai A, Toews GB, Martinez FJ, Flaherty KR. Change in the composite physiologic index predicts mortality in patients with IPF. Am J Respir Crit Care Med 2009;179: A1115.

107. Schmidt LA, Miller M, Flaherty KR, Myers JL. Autopsy Findings in Patients with UIP/IPF – Comparison of Patients with and without Acute Exacerbation (AE). Am J Respir Crit Care Med 2009;179: A2985.

108. Miller MA, Arndt JL, Konkle M, Chenoweth CE, Flaherty KR, Hyzy RC. Polyurethane Cuff Endotracheal Tube to Prevent Ventilator-Associated Pneumonia in an Academic Hospital. Am J Respir Crit Care Med 2009;179: A1731.

109. Schmidt L, Medina E, Flaherty K, Myers J. Usual Interstitial Pneumonia in Lung Resections for Carcinoma. United States and Canadian Academy of Pathology’s 99th Annual Meeting, March 20-26, 2010 in Washington, DC.

110. Schmidt SL, Han MK, Ohtani Y, Toews GB, Martinez FJ, Flaherty KR. Relationship between the presence of an identifiable antigen and fibrosis at the time of diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 2010;181:A4658.

111. White ES, Cornet AM, Yan M, Sagana R, Flaherty KR, Toews GB, Moore B, Martinez FJ. An alternatively-spliced isoform of fibronectin as a potential biomarker in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:A1113.

112. Han MK, Bach DS, Hagan P, Toews GB, Edward R, Anstrom K, Flaherty KR, Martinez FJ. Gender differences in pulmonary hypertension in IPF: An analysis of the STEP-IPF Trial. Am J Respir Crit Care Med 2010;181:A1112.

113. Schmidt SL, Sundaram B, Tayob N, Han MK, Nambiar A, Kazerooni EA, Gross BH, Chughtai A, Myers JL, Flint A, Murray S, Toews GB, Martinez FJ, Flaherty KR. Longitudinal changes in the composite physiologic index and pulmonary function in patients with idiopathic pulmonary fibrosis and emphysema. Am J Respir Crit Care Med 2010;181:A1122.


114. Reineck LA, Sundaram B, Schmidt SL, Han MK, Schmidt LA, Myers JL, Toews GB, Martinez FJ, Flaherty KR. Clinical and radiologic characterization of patients with non-classifiable interstitial pneumonias. Am J Respir Crit Care Med. 2010;181:A1124.

115. Schmidt SL, Tayob N, Han MK, Ohtani Y, Murray S, Toews GB, Martinez FJ, Flaherty KR. Prospective laboratory evaluation for collagen vascular disease in the patients ultimately diagnosed with nonspecific interstitial pneumonia. Am J Respir Crit Care Med. 2010;181:A2496.

116. Schmidt SL, Han MK, Ohtani Y, Toews GB, Martinez FJ, Flaherty KR. High resolution computed tomography and surgical lung biopsy findings often prompt clinicians to consider a diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2010;181:A4659.

117. Han M, Flaherty K, Toews G, Edwards R, Anstrom K, Martinez F. Different patterns of diffuse parenchymal lung disease European Respiratory Congress, 2010 http://www.erscongress2010.org/1063-abstracts.htm.

118. Flaherty KR, Lynch D, van Beek EJR, Kazerooni EA, Gou J, Martinez FJ, Hoffman EA. Training Lung Texture Analysis Software: Thoracic Radiologist Agreement on Patterns in Idiopathic Pulmonary Fibrosis (IPF) on Multidetector volumetric HRCT examinations. European Respiratory Congress, 2010 http://www.erscongress2010.org/1063-abstracts.htm.

119. Raghu G, Behr J, Brown K, Egan J, Flaherty K, Kuwat S, Martinez F, Wells A, Zisman D DeVries, Appleton B, Dean L. Pulmonary Hypertension (PH) in Patients with Idiopathic Pulmonary Fibrosis in Early Course Disease: A Prospective Evaluation with Right Heart Catheterization (RHC) in the ARTEMIS-IPF Study. European Respiratory Conference, 2010 http://www.erscongress2010.org/1063-abstracts.htm.

120. Panetta N, Criner GJ, Toews GB, Martinez FJ, Moore BB, Murray S, Spino C, Courey A, Flaherty KR. Risk factors for pneumothorax during transbronchial biopsy in IPF: Lessons from the COMET Trial. Am J Repir Crit Care Med. 2011;183:A3817.

121. White ES, Cornett AM, Cheng L, Dreffs AA, Yan M, Sagana RL, Booth AJ, Moore BB, Lama VN, Hogaboam CM, Schmidt SL, Toews GB, Flaherty KR, Martinez FJ, Kurtis JD. High-throughput plasma biomarker analysis in IPF reveals an extracellular matrix remodeling signature. Am J Repir Crit Care Med. 2011;183:A2267

122. Flaherty KR, Lynch DA, Van Beek E, Kazerooni EA, Guo J, Martinez FJ, Hoffman EA. Training lung texture analysis software: Impact of radiologist agreement in selecting training volumes of interest (VOI). Am J Repir Crit Care Med. 2011;183:A3819.

123. Richeldi L, Brown KK, Costabel U, Flaherty KR, Kim D, Noble PW, Raghu G, Selman M, Gupta A, Brun M, Kluglich M, Juhel N, du Bois RM. Treatment with BIPF 1120 reduces acute exacerbations and improves quality of life in patients with IPF: Results from the tomorrow study. Am J Repir Crit Care Med. 2011;183:A3809.

124. Richeldi L, Brown KK, Costabel U, Flaherty KR, Kim D, Noble PW, Raghu G, Selman M, Gupta A, Brun M, Kluglich M, Juhel N, du Bois RM. The oral triple kinase inhibitor BIPF 1120 reduces decline in lung function in patients with idiopathic pulmonary fibrosis (IPF): Results from the Tomorrow Study. Am J Repir Crit Care Med. 2011;183:A5303.

125. Han MK, Bach D, Hagan P, Schmidt SL, Flaherty KR, Toews GB, Edwards R, Yow E, Anstrom K, Martinez FJ. Presence of right ventricular dysfunction modifies treatment response to sildenafil in the STEP-IPF trial. Am J Repir Crit Care Med. 2011;183:A5301.


126. Schmidt SL, Han MK, Tayob N, Zappala C, Kervitsky D, Murray S, Toews GB, Martinez FJ, Wells AU, Brown KK, Flaherty KR. Idiopathic pulmonary fibrosis: Predicting future disease course from past trends in pulmonary function. Am J Repir Crit Care Med. 2011;183:A5299.

127. Schmidt SL, Kleaveland K, Han MK, Toews GB, Martinez FJ, Flaherty KR. Prospectively collected antigen exposures do not differ between patients with hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. Am J Repir Crit Care Med. 2011;183:A3809.

128. Saketkoo LA, Huscher D, Khanna D, Dellaripa PF, Flaherty KR, Matteson EL, Oddis CV, Phillips K, Wells AU, Denton CP, Distler O, Kowal-Bielecka OM, Pittrow D, Christmann R, Sandorfi N, StrandV, Brown KK and Seibold JR. Developing a Diesease Activity and Therapeutic Response Index in Connective Tissue Disease Related Interstitial Lung Disease: Initial Results of a Delphi Exercise. ACR/ARHP Annual Scientific Meeting, Chicago 2011 Oral Presentation.

129. Saketkoo LA, Khanna D, Hushcer D, Dellaripa P, Flaherty K, Matteson E, Oddis C, Wells A, Denton C, Distler O, Kowal-Bielecka O, Sandorfi N, Christmann R, Phillips K, Pittrow D, Strand V, Brown K, Seibold J. Developing a disease activity and therapeutic response index in connective tissue disease-interstitial lung disease (CTD-ILD): Results from a Delphi exercise: Consensus on domains. EULAR 2012

130. Flaherty KR, Lynch D, VanBeek E, Kazerooni EA, Guo J, Hoffman EA. Computer Aided CT Analysis in the PANTHER-IPF Study. International Conference on Lung and Airway Fibrosis 2012. Poster Presentation.

131. White ES, Tayob N, Murray S, Flaherty KR, Kurtis J, Martinez FJ. A Peripheral Blood Extracellular Matrix Biomarker Signature Predicts Disease Progression in IPF. Am J Repir Crit Care Med. 185;2012:A6844.

132. Raghu G, Behr J, Brown KK, Egan J, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells A, Pedersen P, Shao L, Chien J, O’Riordan T. ARTEMIS-IPF: A Placebo-Controlled Trial Of Ambrisentan In Idiopathic Pulmonary Fibrosis. Am J Repir Crit Care Med.185;2012:A3632

133. Saketkoo LA, Huscher D, Khanna D, Dellaripa P, Flaherty KR, Matteson EL, Oddis CV, Phillips K, Wells A, Denton CP, Distler O, Kowal-Bielecka OM, Pittrow D, Strand V, Seibold JR, Brown KK. Developing A Disease Activity And Therapeutic Response Index In Connective Tissue Disease Related To Interstitial Lung Disease: Results From A Delphi Exercise: Consensus On Domains. Am J Repir Crit Care Med. 185;2012:A6610.

134. Richeldi L, Brown KK, Costabel U, Flaherty KR, Kim DS, Noble PW, Raghu G, Selman M, Brun M, Klueglich M, Staines H, du Bois RM. Efficacy Of The Tyrosine Kinase Inhibitor BIBF 1120 In Patients With IPF: Consistent Pattern Of Primary Endpoint Results In Sensitivity Analyses Of The TOMORROW Trial. Am J Repir Crit Care Med. 185;2012:A3633.

135. Moore BB, Moore TA, Fry CD, Arenberg DA, Bozyk PD, Wilke CA, Toews GB, Flaherty KR, Martinez FJ. Fibrocytes Are More Readily Detected In Lung Than Circulation Of IPF Patients. Am J Repir Crit Care Med. 185;2012:A5408.

136. Han MK, Tayob N, Murray S, Flaherty KR, Martinez FJ. Gender Differences In Pulmonary Arterial Artery Measures In IPF: Results Of The COMET Trial. Am J Repir Crit Care Med. 185;2012:A4466.


137. Coley C, Dechert R, Harding S, Paine R, Moss M, Martin GS, Burnham E, Flaherty KR, Standiford T, Hyzy RC. Granulocyte Macrophage Colony Stimulating Factor Is Associated With Decreased Quality Of Life At 180 Days Post-Event When Administered To Patients With Acute Lung Injury. Am J Repir Crit Care Med. 185;2012:A2289.

138. Walker N, Martinez FJ, Flaherty KR, White E, Lama VN. Heterogeneity In Responsiveness Of Mesenchymal Stromal Cell From Individual IPF Patients To mTOR Inhibitor Rapamycin And Its Correlation To Dysregulation In The P13K/PTEN/Akt/mTOR Pathway. Am J Repir Crit Care Med. 185;2012: 2657.

139. Coley C, Dechert R, Harding S, Paine R, Moss M, Martin GS, Flaherty KR, Standiford T, Hyzy RC. Patients Surviving Acute Lung Injury Due To A Direct Lung Injury (ie. Pneumonia And Aspiration) Are More Likely To Develop A Restrictive Ventilatory Defect Up To 180 Days Post-Event. Am J Repir Crit Care Med. 185;2012:A2281.

140. Wadwha A, Martinez FJ, Flaherty KR, Myers J, Lama VN. Resident Mesenchymal Progenitor Cells In Idiopathic Pulmonary Fibrosis. Am J Repir Crit Care Med. 185;2012:A3512.

141. Schroeder LE, Coelho AL, Moore BB, Wilke C, White E, Han MK, Flaherty KR, Toews GB, Martinez FJ, Hogaboam CM. Transbronchial Biopsies Are A Reliable Source Of Lung Fibroblasts Following Shipment From Clinical Centers Acroos The USA. Am J Repir Crit Care Med. 185;2012:A4470.

142. Brown KK, Richeldi L, Costabel U, Flaherty KR, Kim DS, Noble PW, Raghu G, Selman M, Brun M, Klueglich M, Staines H, du Bois RM. Treatment Of IPF With The Tyrosine Kinase Inhibitor BIBF1120: Patient-Reported Outcomes In The TOMORROW Trial. Am J Repir Crit Care Med. 185;2012:A3634.

143. Scott JP, Tayob N, Han MK, Martinez FJ, Murray S, White ES, Flaherty KR. Clinical Outcomes In Patients With Idiopathic Pulmonary Fibrosis: Data From COMET. Am J Repir Crit Care Med. 187;2013:A4332.

144. Martinez FJ, Brown KK, Collard HR, Flaherty KR, King TE, Raghu G, Roman J, Schwarz MI, Yow E, Anstrom KJ. Discrepancy Between Changes In FVC And Disease Progression In Two Prospective Idiopathic Pulmonary Fibrosis (IPF) Therapeutic Trials. Am J Repir Crit Care Med. 187;2013:A2354.

145. Kinney A, Tayob N, Murray S, Bach D, Hagan P, Yow E, Anstrom K, Flaherty KR, Kim SS, Yagihashi K, Lynch DA, Martinez FJ, Han MK. Gender Difference In The STEP-IPF Trial. Am J Repir Crit Care Med. 187;2013:A1092.

146. Guo J, Flaherty KR, VanBeek EJ, Lynch DA, Kazerooni EA, Hoffman EA. Iterative Methods For The Expansion Of Classification Variables And Increasing Generalization Accuracy In Lung Tissue Characterization. Am J Repir Crit Care Med. 187;2013:A5458.

147. Saketkoo LA, Mittoo S, Huscher D, Dellaripa PF, Denton CP, Distler O, Fischer A, Flaherty KR, Frankel S, Khanna D, Kowal-Bielecka OM, LeSage D, Merkel P, Oddis CV, Phillips K, Pittrow D, Sarver C, Sandorfi N, Christmann R, Swigris J, Wells A, Antoniou K, Baughman RP, Castelino FV, Christopher-Stine L, Danoff S, Highland KB, Hummers L, Shah A, Kim DS, Lynch DA, Miller F, Proudman S, Richeli L, Ryu JH, Seibold JR, Strand V, Matteson EL, Brown KK. Provisional Consensus On Domains And Instruments In Connective Tissue Disease Related Interstitial Lung Disease And Idiopathic Pulmonary Fibrosis For Use In Clinical Trials. Am J Repir Crit Care Med. 187;2013:A2352.


148. Han MK, Erb-Downward J, Zhou Y, Tayob N, Murray S, Flaherty KR, Huffnagle GB, Martinez FJ. The IPF Microbiome: Analysis From The COMET Study. Am J Repir Crit Care Med. 187;2013:A3769.

149. Votava J, Belpario J, Kazerooni EA, Lagstein A, Myers JL, Simon RH, Sisson TH, Sundaram B, White ES, Zusman D, Flaherty KR. Utility of Transbronchial Biopsy Versus Surgical Lung Biopsy In The Diagnosis Of Patients With Suspected Idiopathic Interstitial Pneumonia. Am J Repir Crit Care Med. 187;2013:A1089.

150. Saketkoo LA, Mittoo S, Huscher D, Dellaripa PF, Denton CP, Distler O, Fischer A, Flaherty KR, Frankel S, Khanna D, Kowal-Bielecka O, LeSage D, Merkel P, Oddis CV, Phillips K, Pittrow D, Sarver C, Sandorfi N, Christmann N, Swigris J, Wells AU, Antoniou K., Baughman RP, Castelino FV, Christopher-Stine L, Danoff S, Highland KB, Hummers L, Shah A, Kim DS, Lynch D, Miller FW, Proudman S, Richeldi L, Ryu JH, Seibold JR, Strand V, Matteson EL, Brown KK. Provisional Consnesus On Domains and Instruments in Connective Tissue Disease Related Insterstitial Lung Disease and Idiopathic Pulmonary Fibrosis For Use in Clinical Trials. Am J Repir Crit Care Med. 187;2013:39803


Kevin R. Flaherty M.D. - medicine.umich.edu€¦ · Web viewKevin R. Flaherty, M.D., M.S....

Documents

Transcript of Kevin R. Flaherty M.D. - medicine.umich.edu€¦ · Web viewKevin R. Flaherty, M.D., M.S....